January 2016 to December 2022



Apparent Opioid and Stimulant Toxicity Deaths

Surveillance of Opioid and Stimulant-Related Harms in Canada



To promote and protect the health of Canadians through leadership, partnership, innovation and action in public health.

-Public Health Agency of Canada

Prepared by the Substance-related Overdose and Mortality Surveillance Task Group (SOMS-TG) of the Federal, provincial, and territorial Special Advisory Committee (SAC) on the Epidemic of Opioid Overdoses

Également disponible en français sous le titre :

Décès apparemment liés à une intoxication aux opioïdes et aux stimulants Surveillance des méfaits associés aux opioïdes et aux stimulants au Canada Janvier 2016 à décembre 2022

To obtain additional information, please contact:

Public Health Agency of Canada Address Locator 0900C2 Ottawa, ON K1A 0K9 Tel.: 613-957-2991

Toll free: 1-866-225-0709 Fax: 613-941-5366 TTY: 1-800-465-7735

E-mail: publications-publications@hc-sc.gc.ca

© His Majesty the King in Right of Canada, as represented by the Minister of Health, 2023

Publication date: June 2023

This publication may be reproduced for personal or internal use only without permission provided the source is fully acknowledged.

Cat.: HP33-7E-PDF ISSN: 2816-2307 Pub.: 230047



Table of Contents

Acknowledgements	4
Suggested Citation	5
Key Findings	6
Technical Notes	9
Definitions	9
How apparent opioid and stimulant toxicity deaths are counted. Limitations of the data on apparent opioid and/or stimulant toxicity deaths	11 12
•	13
General notes	13
Manner of death	14
Sex and age group.	14
Fentanyl, fentanyl analogues, and non-fentanyl opioids	14
Origin of opioid(s)	15
Cocaine, methamphetamine and other stimulants	16 16
Table A. Reporting periods, manners of death, and availability of opioid and stimulant data included in this update by province or territory	18 20
Appendix	21
Table 1a. Number and rate (per 100,000 population) of total apparent opioid toxicity deaths by province or territory, 2016 to 2022	22
	25
	27
	30
•	32
Table 3b. Percentage of apparent stimulant toxicity deaths in Canada by manner of death, 2018 to 2022	32



Table 4a. Summary of total apparent opioid toxicity deaths in Canada, 2016 to 2022.	33
Table 4b. Summary of total apparent stimulant toxicity deaths in Canada, 2018 to 2022	34
Table 5a. Number of total apparent opioid toxicity deaths by quarter and province or	
territory, January 2016 to December 2022	35
Table 5b. Number of total apparent stimulant toxicity deaths by quarter and province or	
territory, January 2018 to December 2022	38
Table 6a. Number of accidental apparent opioid toxicity deaths by quarter and province	
or territory, January 2016 to December 2022	40
Table 6b. Number of accidental apparent stimulant toxicity deaths by quarter and	
province or territory, January 2018 to December 2022	43
Table 7a. Percentage of accidental apparent opioid toxicity deaths by sex and province	
or territory, 2016 to 2022	45
Table 7b. Percentage of accidental apparent stimulant toxicity deaths by sex and	40
province or territory, 2018 to 2022	46
Table 8a. Crude rate (per 100,000 population) of accidental apparent opioid toxicity	47
deaths by sex and province or territory, 2016 to 2022.	47
Table 8b. Crude rate (per 100,000 population) of accidental apparent stimulant toxicity deaths by sex and province or territory, 2018 to 2022.	48
Table 9a. Percentage of accidental apparent opioid toxicity deaths by age group and	40
province or territory, 2016 to 2022	49
Table 9b. Percentage of accidental apparent stimulant toxicity deaths by age group and	10
province or territory, 2018 to 2022	56
Table 10a. Percentage of accidental apparent opioid toxicity deaths by type of opioids	
and province or territory, 2016 to 2022	59
Table 10b. Percentage of accidental apparent stimulant toxicity deaths by type of	
stimulants and province or territory, 2018 to 2022	62
Table 11a. Percentage of accidental apparent opioid toxicity deaths involving stimulants,	
by province or territory, 2018 to 2022	64
Table 11b. Percentage of accidental apparent stimulant toxicity deaths involving opioids,	
by province or territory, 2018 to 2022	65
Table 12a. Percentage of accidental apparent opioid toxicity deaths involving other	
psychoactive substances, by province or territory, 2016 to 2022	66
Table 12b. Percentage of accidental apparent stimulant toxicity deaths involving other	
psychoactive substances, by province or territory, 2018 to 2022	67
Table 13. Percentage of accidental apparent opioid toxicity deaths by origin of opioid(s),	0.0
by province or territory, 2018 to 2022	68
Table 14a. Number of accidental apparent opioid toxicity deaths by sex and age group,	70
by province or territory, 2018 to 2022	73
Table 14b. Number of accidental apparent stimulant toxicity deaths by sex and	78
age group, by province or territory, 2018 to 2022	70
Table 15a. Percentage of accidental apparent opioid toxicity deaths by type of opioids and sex, by province or territory, 2018 to 2022.	83
and son, by province or territory, zoro to zozz	J



Table 15b. Percentage of accidental apparent stimulant toxicity deaths by type of stimulants and sex, by province or territory, 2018 to 2022	85
Table 16a. Percentage of accidental apparent opioid toxicity deaths by type of opioids and age group, by province or territory, 2018 to 2022.	87
Table 16b. Percentage of accidental apparent stimulant toxicity deaths by type of stimulants and age group, by province or territory, 2018 to 2022	97
Table 17. Percentage of accidental apparent opioid toxicity deaths by type of opioids and origin of opioid(s), by province or territory, 2018 to 2022	107
Table 18. Percentage of accidental apparent opioid toxicity deaths by sex and origin of opioid(s), by province or territory, 2018 to 2022	117



Acknowledgements

This update would not be possible without the collaboration and dedication of provincial and territorial (PT) offices of Chief Coroners and Chief Medical Examiners as well as PT public health and health partners and Emergency Medical Services data providers. We would also like to acknowledge the Canadian Institute for Health Information (CIHI) for collecting and providing the data used for reporting opioid- and stimulant-related poisoning hospitalizations.



Suggested Citation

Federal, provincial, and territorial Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid- and Stimulant-related Harms in Canada. Ottawa: Public Health Agency of Canada; June 2023. https://health-infobase.canada.ca/substance-related-harms/opioids-stimulants/



Key Findings

Context

Canada has seen substantially elevated numbers of opioid-related deaths and other harms since surveillance began in 2016 by the Public Health Agency of Canada. This public health crisis is having a tragic impact on people who use substances, their families, and communities across the country, and is shaped by a wide range of factors. There is evidence the COVID-19 pandemic has contributed to and exacerbated the crisis, with several jurisdictions reporting higher rates of fatal overdoses and other harms following the onset of the pandemic.

Presented here are the most recent available data on overdoses and deaths involving opioids and/or stimulants from January 2016 to December 2022 in Canada, where available. Recognizing that harms related to opioids, stimulants, and other substances extend beyond overdoses (poisonings) and deaths, we continue to work with federal, provincial and territorial partners to build a broad understanding of harms and substances involved to better respond to this public health crisis. Additional studies can also help us plan and tailor actions to achieve better possible outcomes.

What: There was a total of 36,442 apparent opioid toxicity deaths between January 2016 and December 2022^{1,2}

- + A total of 7,328 apparent opioid toxicity deaths occurred in 2022 (January-December). This is an average of 20 deaths per day. In 2019 prior to the COVID-19 pandemic, the average number of deaths per day was 10, which increased to a peak of 22 in 2021.
- + The number of total apparent opioid toxicity deaths in Canada reported in 2022 (January-December) has been lower (9%) than the previous year. This is based on preliminary data subject to change as death investigations are completed and reported. However, based on current national data, analyses show there has been no significant decrease in trend and rates remain high.

¹ Manitoba data from April to December 2022 were not available at the time of this update.

² The national overall count from January 2016 to December 2022 includes deaths from British Columbia (2019 to 2022) related to all illicit drugs and Quebec (2021 and 2022) related to drug or opioid-related intoxication.



Where: A majority of deaths occurred in British Columbia, Alberta, and Ontario; high rates were also observed within other regions

- + In 2022 (January-December), most (87%) of all accidental apparent opioid toxicity deaths in Canada occurred in British Columbia, Alberta, and Ontario.
- + Elevated mortality rates have also been observed in other areas with smaller population sizes, including Saskatchewan and Yukon.

Who: Most apparent opioid toxicity deaths among young- to middle-aged males

- + Males accounted for the majority of accidental apparent opioid toxicity deaths (74%) in 2022 (January-December).
- + For males and for females, the majority of accidental apparent opioid toxicity deaths were among individuals aged 20 to 59 years.

Why: Among other drivers, toxicity of supply continues to be a major driver of the crisis

- + Of all accidental apparent opioid toxicity deaths in 2022 (January-December), 81% involved fentanyl.
- + Of all accidental apparent opioid toxicity deaths in 2022 (January-December), 79% involved opioids that were only non-pharmaceutical^{3,4}.

³ Based on 2022 data on origin of opioids from deaths with completed investigations from ten provinces or territories.

Opioids with a pharmaceutical origin refer to opioids that were manufactured by a pharmaceutical company and approved for medical purposes in humans. Pharmaceutical origin does not indicate how the opioids were obtained (e.g., through personal prescription or by other means).



Data on the polysubstance nature of the overdose crisis

- + Available information from eight provinces and territories indicates the number of apparent stimulant toxicity deaths in 2022 (January-December) was high. Almost all (98%) of those deaths were accidental.
- + Over half (56%) of accidental apparent opioid toxicity deaths in 2022 (January-December) also involved a stimulant, reflecting the polysubstance nature of this crisis.
- + Of the accidental apparent stimulant toxicity deaths in 2022 (January-December), 64% involved cocaine, while 53% involved methamphetamines.

Data on apparent opioid and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those values would result in an overestimation of the burden of opioids and stimulants.

+ Of the accidental apparent stimulant toxicity deaths in 2022 (January-December), 78% involved an opioid.



This update is based on data submitted to the Public Health Agency of Canada on or before May 3, 2023. Due to differences in identifying and reporting cases, comparisons over time and between provinces and territories should be interpreted with caution. Refer to the Technical Notes for more information.



Technical Notes

Definitions

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Ongoing investigation: Coroners and medical examiners continue to collect information on how and why the death occurred. Data for ongoing investigations are considered preliminary and subject to change.

Completed investigation: Coroners and medical examiners have collected all available information on how and why a death occurred. The time required to complete an investigation and related administrative processes is case-dependent and can range from approximately three to twenty-four months.

Manner of death – Accident: Deaths with completed investigations where the coroner or medical examiner determined that the death was unintentional. This category also includes deaths with ongoing investigations where the manner of death was believed to be unintentional or had not been assigned at the time of reporting.

Manner of death – Suicide: Deaths with completed investigations where the coroner or medical examiner determined that the opioids were consumed with the intent to die. This category also includes deaths with ongoing investigations where suicide was believed to be the manner of death at the time of reporting.

Manner of death – Undetermined: Deaths with completed investigations where a specific manner of death (e.g., accident, suicide) could not be assigned based on available or competing information. For this manner of death category, provinces and territories report only completed investigations with the exception of British Columbia which also includes data from ongoing investigations.

Opioid origin – Pharmaceutical: Deaths with completed investigations where all opioids that directly contributed to death were manufactured by a pharmaceutical company and approved for medical purposes in humans. Pharmaceutical origin does not indicate how the opioids were obtained (e.g., through personal prescription or by other means).

Opioid origin – Non-pharmaceutical: Deaths with completed investigations where all opioids that directly contributed to the death were not manufactured by a pharmaceutical company or not approved for medical purposes in humans.



Opioid origin – Both pharmaceutical and non-pharmaceutical: Deaths with completed investigations where the opioids that directly contributed to the death were a combination of pharmaceutical and non-pharmaceutical opioids, without any opioids of undetermined origin.

Opioid origin – Undetermined: Deaths with completed investigations where, for one or more opioids that directly contributed to the death, it was not possible to determine whether the opioid was pharmaceutical or non-pharmaceutical.



How apparent opioid and stimulant toxicity deaths are counted

Counts or record-level information are provided by the provinces and territories that collect data from their respective offices of Chief Coroners or Chief Medical Examiners. Crude and age-adjusted rates are calculated using the most current population data from Statistics Canada. Age-adjusted rates used the 2016 Canadian population as a reference and direct standardization was applied.

Crude rates: summarize the situation within a region at a certain time period and have not been adjusted for existing differences by provincial and territorial age distributions (e.g., (number of deaths / population) x 100,000).

Age-adjusted rates: have been adjusted for existing differences by provincial and territorial age distributions using the 2016 Canadian population as a reference. These rates assume that all regions have the same age distributions and are useful when comparing between regions and over time.

The data provided by the provinces and territories can include deaths:

- + with completed or ongoing investigations
- + where manner of death is classified as accident, suicide, or undetermined

These data **do not** include deaths due to:

- + the medical consequences of long-term substance use or overuse (for example, alcoholic cirrhosis)
- + medical assistance in dying
- + trauma where use of the substance(s) contributed to the circumstances of the injury that lead to the death, but was not directly involved in the death
- + homicide

However, some provincial and territorial differences remain in the type of data reported and in the time periods for which data are available (refer to Table A).



Limitations of the data on apparent opioid and/ or stimulant toxicity deaths

Data presented in this update should be interpreted with caution.

- + This update is based on data submitted to the Public Health Agency of Canada on or before May 3, 2023. New or revised data reported after this date will be reflected in future updates.
- + Data released by provinces and territories may differ due to the availability of updated data, differences in the type of data reported (e.g., manners of death), the use of alternate age groupings, differences in time periods presented and/or population estimates used for calculations, etc.
- + As some data are based on ongoing investigations by coroners and medical examiners, they are considered preliminary and subject to change. The time required to complete an investigation and related administrative processes is case-dependent and can range from approximately three to twenty-four months.
- + This update is based on data that do not specify how the opioids or stimulant were obtained (e.g., illegally or through personal prescription); the level of toxicity may differ depending on the opioid or stimulant (substance(s) involved, concentration, and dosage).
- + Provincial and territorial differences in the death investigation process, death classification method, toxicology testing, and the manners of death reported may impact the interpretation and comparability of the data presented in this update over time and between provinces and territories.
- + Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.
- + Provinces and territories are included in calculations of national crude and age-adjusted rates if they have submitted data for at least one quarter of a given year.
- + Quarterly totals for Canada may not equal the annual totals due to suppressed data for some provinces and territories with low number of deaths.
- + Data on apparent stimulant toxicity deaths were only available from five to eight provinces and territories depending on the year. Therefore, national numbers and rates are not provided in this update. Refer to Table A for more details.



Notes on provincial and territorial data

Due to differences in identifying and reporting cases, comparisons over time and between provinces and territories should be interpreted with caution.

General notes

- 1. Data reported by some provinces and territories do not include all manners of death (accident, suicide, or undetermined) or stages of investigation (ongoing or completed); refer to Table A for more details.
- 2. Rates for provinces and territories with relatively smaller populations may change substantially with even slight changes in the number of deaths.
- 3. British Columbia data from 2016 to 2018 include deaths with completed investigations only. Overall numbers for British Columbia from 2019 to 2022 include deaths with ongoing investigations related to all illicit drugs, including but not limited to opioids and stimulants, used alone or in combination with prescribed/diverted medication. However, stratified data (e.g., by sex, age group, etc.) are based only on opioid toxicity deaths for which investigations are completed.
- 4. Quebec data from 2016 to 2020 include deaths with completed investigations only; death investigations were underway for 3% in 2020. These data encompass deaths that are attributable to opioids for apparent opioid toxicity deaths and deaths that are attributable to stimulants for apparent stimulant toxicity deaths. Available 2021 and 2022 data from Quebec include unintentional deaths with ongoing investigations. These data encompass deaths related to drug or opioid-related intoxication, including, but not limited to, opioids and stimulants. Preliminary data for drug-related poisonings, for which toxicology information was available, indicate that 51% of deaths between January 2021 and December 2022 involved an opioid.
- 5. Data from Yukon include deaths with completed investigations only. Between 2016 and 2022, two apparent opioid toxicity deaths occurred in a different province following an overdose in Yukon. These deaths are included in the data from the jurisdiction where the deaths occurred and are not reported in the data from Yukon.
- 6. Data from Prince Edward Island include accidental deaths with completed investigations only. Only annual totals were available for 2016 data from Prince Edward Island; quarterly data for 2016 were not available at the time of this update.
- 7. In Ontario, apparent opioid toxicity death data were captured using an enhanced data collection tool by the Office of the Chief Coroner (OCC) as of May 1, 2017. Prior to this, retrospective case information was collected using a different tool. Effective September 1, 2021, apparent opioid toxicity death data are captured in the OCC's new case management system for death investigations.
- 8. For Newfoundland and Labrador, data on apparent opioid toxicity deaths between January 2016 and December 2019 were based on the detection of opioids as indicated on the toxicological report. As of 2020, data include deaths where opioids directly contributed to the death.
- 9. Data from Nunavut were not included in national counts or percentages.
- 10. Manitoba data from April to December 2022 were not available at the time of this update.



Manner of death

- 11. Manner of death is assigned by the coroner or medical examiner during or following an investigation. The data in this update include deaths with a manner of accident, suicide, or undetermined.
- 12. Suicide data were unavailable from Alberta (2018 to 2022), Prince Edward Island and Nunavut.

Sex and age group

- 13. For most provinces and territories, data on the sex of the individual was based on biological characteristics or legal documentation.
- 14. Data on deaths where sex was categorized as "Other" were excluded from analyses by sex but were included in overall analyses.
- 15. Due to rounding, percentages may not add to 100%.
- 16. For Ontario, from January 2016 to April 2017, sex reflected the sex assigned at birth or biological characteristics at the time of death. From May 2017 to December 2017, sex reflected the perceived or projected identity of the individual. As of January 2018, sex reflects the sex assigned at birth or biological characteristics at the time of death.
- 17. Alberta uses data on the sex of the individual based on the medical examiner's assessment, which is largely based on biological characteristics. In a small subset of cases where the individual was known to identify with a gender different than their biological sex, the medical examiner may indicate their identified gender.
- 18. Data on deaths where age group was categorized as "Unknown" were excluded from analyses by age group but were included in overall analyses.

Fentanyl, fentanyl analogues, and non-fentanyl opioids

- 19. Refer to Table B below for details on opioids.
- 20. Prior to 2018, the percentage of deaths involving fentanyl and/or fentanyl analogues represented a single category. For data reported for 2018 to 2022, some provinces and territories did not report fentanyl analogue information or required additional information to differentiate fentanyl from fentanyl analogues until investigations are completed. Therefore, deaths involving fentanyl analogues may be included in the fentanyl percentages for some jurisdictions.
- 21. The sum of percentages by type of opioid may not add up to 100% because a death may involve more than one type of opioid.
- 22. Observed trends of accidental apparent opioid toxicity deaths involving fentanyl or fentanyl analogues should be interpreted with caution until additional data become available. In addition, changes to testing practices during the reporting period may affect observed trends.
- 23. Given provincial and territorial differences in death classification methods, the term "involving" includes deaths where the substance was either detected and/or directly contributed to the death. Substances can be detected through toxicology testing and may or may not have directly contributed to the death. Direct contribution to the death is based on investigation by coroner or medical examiner.



- 24. Available 2021 and 2022 data from Quebec on deaths related to drugs or opioid toxicity where toxicology information was available and fentanyl (or fentanyl analogues) was detected were used to approximate apparent opioid toxicity deaths involving fentanyl (or fentanyl analogues), among deaths where opioids were detected.
- 25. For Alberta, only data on deaths with completed investigations, where relevant toxicology information was available, were included in percentages for fentanyl, fentanyl analogues, or non-fentanyl opioids.
- 26. For Ontario, only data on deaths where a cause of death was available were included in percentages for fentanyl, fentanyl analogues, or non-fentanyl opioids.

Origin of opioid(s)

- 27. The origin of opioid(s) refers to whether the opioids that directly contributed to the death were pharmaceutical, non-pharmaceutical, both or undetermined.
- 28. Data on origin were only available for deaths with completed investigations from 2018 onward from between seven and ten provinces and territories, depending on the year. Completed investigations represented 77% of accidental apparent opioid toxicity death investigations from these provinces and territories over that period; refer to Table A for more details.
- 29. Summary data and trends based on origin of opioid(s) should be interpreted with caution until additional data become available.
- 30. Origin categorization is based on toxicology results and scene evidence and does not indicate how the substances were prepared, their appearance, or how they were "advertised"; nor should it be used to infer the timing or mode of consumption.
- 31. Pharmaceutical opioids also include those approved for use in humans in other countries, but not necessarily in Canada.
- 32. For the purposes of origin categorization, deaths involving fentanyl are categorized as "suspected non-pharmaceutical" when there is: 1) no evidence of a patch, vial, or other pharmaceutical formulation at the scene, or 2) no/unknown evidence of a prescription. These deaths are grouped with deaths involving non-pharmaceutical opioids.
- 33. Origin categorization represents the best estimate based on the information available and should be interpreted with caution.
- 34. Origin refers only to the opioid(s) involved in death and should not be used as an indication of prior use of opioids of the same or other origin.
- 35. British Columbia only reports apparent opioid toxicity deaths involving any illicit opioid(s), resulting in a high proportion of non-pharmaceutical opioids. For that reason, data on origin of opioids from British Columbia were not included in the national proportions.



Cocaine, methamphetamine and other stimulants

- 36. Refer to Table B below for details on stimulants.
- 37. Amphetamine is a known metabolite of methamphetamine but can also be consumed separately and directly contribute to a toxicity death. Deaths where amphetamine (without methamphetamine) directly contributed to the death are reported under "other stimulants". In situations where both methamphetamine and amphetamine were consumed separately, and both directly contributed to death, the death is reported under both methamphetamine and "other stimulants"
- 38. Data on apparent stimulant toxicity deaths were available from between five and eight provinces and territories, depending on the year from 2018 to 2022.
- 39. The sum of percentages by type of stimulant may not add up to 100% because a death may involve more than one type of stimulant.
- 40. For Ontario, only data on deaths where a cause of death was available were included in percentages for cocaine, methamphetamine, and other stimulants.
- 41. Data from Quebec on "other stimulants" include deaths involving methamphetamine.
- 42. For Alberta, only apparent opioid toxicity deaths with completed investigations are used in the numerator for percentage of deaths involving stimulants. As a result, these values may change when more investigations are completed.

Other psychoactive substances

- 43. Refer to Table B below for details on other psychoactive substances.
- 44. For Alberta, only data on deaths with completed investigations, where specific substances causing death were listed on the death certificate, were included in percentages of accidental apparent opioid toxicity deaths involving other non-opioid substances.
- 45. For Ontario, only data on deaths with completed investigations, where relevant toxicology information was available, were included in percentages of accidental apparent opioid toxicity deaths involving other non-opioid substances. Data for non-opioid substances from Ontario between January 2016 and April 2017 were based on their detection and do not include alcohol; as of May 1, 2017, data on non-opioid substances are based on their direct effects and include alcohol.



Data suppression

The suppression of data in this update is based on the preferences of individual provinces or territories to address concerns around releasing small numbers for their jurisdiction.

- + Quebec suppressed counts less than five for deaths with ongoing investigations (2021 and 2022).
- + Nova Scotia suppressed all counts for age group 0 to 19 years when stratified by sex.
- + Prince Edward Island suppressed counts between one and four for quarterly data, and for any data related to sex or age distribution.
- + Newfoundland and Labrador suppressed counts between one and four for quarterly data, and data related to substances involved and sex or age distribution.
- + Yukon suppressed counts between one and four for data related to sex or age distribution.
- + Nunavut suppressed all counts less than five.

In addition, suppression was applied in some instances where all data for a province or territory fell in a single category of a given table or figure.

Table A. Reporting periods, manners of death, and availability of opioid and stimulant data included in this update by province or territory

		вс	АВ	SK	МВ	ON	QC	NB	NS	PE	NL	ΥT	NT	NU
Available d	lata on apparent toxicity death	ns invo	lving o	pioids	as of M	ay 3, 2	023			'	!			
2016-18	January to December	(C)	~	(C)	~	~	(C)	~	~	(C)	(C)	(C)	~	~
2019	January to December	~	~	(C)	~	>	(C)	~	~	(C)	(C)	(C)	~	~
2020	January to December	~	~	(C)	~	~	(C)	~	~	(C)	(C)	(C)	~	•
2021	January to December	~	~	(C)	~	~	~	~	~	(C)	(C)	(C)	~	~
2022	January to December	~	~	(C)	(INC)	~	~	~	~	(C)	(C)	(C)	~	•
Available d	lata on apparent toxicity death	ns invo	lving st	timulaı	nts as o	f May 3	3, 2023							
2018	January to December	(C)	n/a	(C)	n/a	>	(C)	n/a	~	n/a	n/a	n/a	n/a	n/a
2019	January to December	(C)	n/a	(C)	~	>	(C)	n/a	~	n/a	n/a	n/a	n/a	n/a
2020	January to December	(C)	n/a	(C)	~	>	(C)	n/a	~	n/a	(C)	n/a	~	n/a
2021	January to December	(C)	n/a	(C)	~	~	n/a	n/a	~	n/a	(C)	(C)	~	n/a
2022	January to December	(C)	n/a	(C)	(INC)	~	n/a	n/a	~	n/a	(C)	(C)	~	n/a
Classificat	ion of deaths included in the	report	ed data	a										
	Completed investigations	~	~	~	~	~	~	~	~	~	~	~	~	~
Accident	Ongoing investigations where manner of death was believed to be unintentional	~	-	n/a	~	-	~	~	~	n/a	n/a	n/a	~	n/a
	Ongoing investigations where manner of death had not been assigned at the time of reporting	-	~	n/a	~	~	n/a	~	~	n/a	-	-	~	n/a
	Completed investigations	~	(INC)	~	~	~	~	~	~	n/a	~	~	~	~
Suicide	Ongoing investigations where the manner of death was believed to be suicide	~	n/a	n/a	~	-	n/a	~	~	n/a	n/a	n/a	~	n/a

		вс	АВ	SK	МВ	ON	QC	NB	NS	PE	NL	ΥT	NT	NU
	completed investigations and nined manner of death	~	~	~	~	~	~	~	~	n/a	~	~	~	~
Available d	lata on origin of the opioid(s)													
2018	January to December	~	~	~	n/a	~	n/a	~	~	n/a	n/a	n/a	n/a	n/a
2019	January to December	~	~	~	~	~	n/a	~	~	n/a	n/a	n/a	n/a	n/a
2020	January to December	~	~	~	~	~	n/a	~	~	n/a	~	n/a	n/a	n/a
2021	January to December	~	~	~	~	~	n/a	~	~	~	~	n/a	~	n/a
2022	January to December	~	~	~	(INC)	~	n/a	~	~	~	~	n/a	~	n/a

[✓] These data have been reported by the province or territory and are reflected in this update, unless otherwise specified

⁽C) Data includes deaths with completed investigations only

⁽INC) Data was not available for the entire period

The classification is not used in the province or territory

n/a Data were not available at the time of this publication

Table B. Types of opioids and stimulants

Category	Includes (but are not limited to):	
Fentanyl and fentanyl analogues	+ 3-methylfentanyl + acetylfentanyl + acrylfentanyl + butyrylfentanyl + carfentanil + crotonyl fentanyl + cyclopropyl fentanyl	 + despropionyl-fentanyl + fentanyl + fluoroisobutyrlfentanyl (FIBF) + furanylfentanyl + methoxyacetylfentanyl + norfentanyl
Non-fentanyl opioids	+ 2-methyl AP-237 + AH-7921 + AP-237 + brorphine + buprenorphine metabolites + codeine + desomorphine + dihydrocodeine + etodesnitazene + heroin + hydrocodone + hydromorphone + isopropyl-U-47700 + isotonitazene + loperamide	 + meperidine + methadone + metonitazene + mitragynine + monoacetylmorphine + morphine + MT-45 + normeperidine + oxycodone + tapentadol + tramadol + U-47700 + U-49900 + U-50488
Stimulants	+ amphetamine + atomoxetine + catha + cocaine + dexamfetamine + ethylphenidate + lisdexamfetamine + MDA + MDMA	 + mephedrone + methamphetamine + methylphenidate + modafinil + pemoline + phentermine + pseudoephedrine + TFMPP
Other psychoactive substances	+ alcohol+ benzodiazepines+ gabapentinoids+ ketamine+ LSD	+ PCP + psilocin + W-18 + Z-drugs

Appendix



 Table 1a.
 Number and rate (per 100,000 population) of total apparent opioid toxicity deaths by province or territory, 2016 to 2022

		2016			2017			2018	
Province or territory	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population
BC	908	16.6	16.5	1,296	56.3	26.1	1,354	27.0	26.9
AB	602	14.3	13.8	744	5'21	17.0	805	18.7	18.3
SK	83	7.3	2.5	85	7,4	9'2	126	10.8	11,4
MB	88	2'9	6.8	106	6'2	8.1	93	6'9	7.0
NO	867	6.2	6.3	1,265	0'6	0'6	1,507	10,5	10.6
QC	263	3.2	3.2	280	3,4	3,4	211	2.5	2.5
NB	34	4.5	4,4	38	2'0	5.1	30	3,9	3,9
NS	53	5.6	5.7	64	2'9	6'9	54	5.6	5.8
PE	5	3,4	3.2	5	8'8	3.6	8	5.2	5,4
NL	18	3,4	3.6	33	6.2	6.5	12	2.3	2.3
YT	7	18.2	17.5	7	17.7	16.6	5	12.3	12,4
NT	5	11.2	12.2	1	2.2	1,9	2	4,4	3,8
NU	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Canada	2,831	7.8	7.8	3,924	10.7	10.8	4,207	11.4	11.4

		2019			2020			2021	
Province or territory	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population
BC	1,019	20.0	19.9	1,795	34.8	34.8	2,334	44.9	44.8
AB	626	14.3	14.1	1,185	26.8	26.7	1,626	36.6	36.2
SK	117	10.0	10.6	268	22.7	23.8	332	28.1	29.9
MB	62	4.5	4.6	260	18,8	19.3	270	19,4	19.8
NO	1,558	10.7	10.8	2,459	16.7	16.8	2,854	19,3	19.4
QC	211	2.5	2.5	319	2'8	3.7	450	5.2	5,3
NB	35	4.5	4.6	45	2'2	5.9	44	5.6	5,8
NS	22	5.9	5,9	50	5.1	5.3	39	3.9	4.0
PE	5	3.2	3,3	8	5.0	4.9	12	7.3	8.2
NL	18	3.4	3,5	24	4.6	4.9	25	4.8	5.2
YT	4	9.7	10.0	10	23.7	23.3	23	53.2	49,6
NT	1	2.2	2.1	3	6.6	5.8	4	8'8	8.0
NU	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Canada	3,713	6'6	10.0	6,426	16.9	17.1	8,013	21.0	21.3

		2022	
Province or territory	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population
BC	2,342	44.0	44.0
AB	1,499	33.0	32.6
SK	235	19.7	20,9
MB	52	3.7	3.8
NO	2,501	16.6	16.7
QC	541	6.2	6.3
NB	46	5.7	6.1
NS	62	6.1	6.1
PE	4	2.3	2.2
NL	24	4,6	4.8
YT	19	43,4	40,4
NT	3	6,6	6.1
NU	Suppr.	Suppr.	Suppr.
Canada	7,328	18.8	19.1

Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules. Suppressed (Suppr.) Not available (n/a)

Data were not available at the time of this publication.

includes deaths related to all illicit drugs including, but not limited to, opioids and stimulants.

includes deaths related to all drug or opioid intoxications including, but not limited to, opioids and stimulants.

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

Table 1b. Number and rate (per 100,000 population) of total apparent stimulant toxicity deaths by province or territory, 2018 to 2022

		2018			2019			2020	
Province or territory	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population
BC	1,068	21.3	21.2	498	8'6	2'6	663	19.3	19.3
SK	84	7.2	7.5	95	8.1	8,3	184	15.6	16.3
MB	n/a	n/a	n/a	81	5,9	0'9	249	18.0	18,4
ON	916	6.4	6,4	1,025	7.0	7.1	1,728	11.7	11,9
QC	163	1.9	2.0	142	1.7	1.7	193	2.3	2.3
NS	25	2.6	2,8	29	3.0	3.1	35	3.6	3.7
NL	n/a	n/a	n/a	n/a	n/a	n/a	10	1,9	2.2
YT	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
NT	n/a	n/a	n/a	n/a	n/a	n/a	3	9'9	5,8

		2021			2022	
Province or territory	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population
BC	212	13.8	13.8	189	3.6	3.6
SK	268	22.7	23.9	182	15.2	16.0
MB	281	20.2	20.7	20	3.5	3.6
NO	2,083	14.1	14.2	1,811	12.0	12.1
QC	n/a	n/a	n/a	n/a	n/a	n/a
NS	34	3,4	3,6	45	4,4	4.5
NL	16	3.1	3,3	14	2.7	2.8
YT	9	13.9	12.6	15	34.3	33.5
NT	3	9'9	6.1	3	9'9	6.1

Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules. Suppressed (Suppr.) Not available (n/a)

Data were not available at the time of this publication.

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved. Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

Table 2a. Number and rate (per 100,000 population) of accidental apparent opioid toxicity deaths by province or territory, 2016 to 2022

		2016			2017			2018	
Province or territory	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population
BC	062	16,3	16.1	1,274	8'52	25.7	1,340	26.7	26.6
AB	247	13.0	12,4	683	1'91	15,5	799	18,6	18.2
SK	9/	2'9	6'9	74	6,4	9'9	114	8'6	10.3
MB	61	4,6	4.7	87	6.5	9'9	78	5.8	5,8
NO	726	5.2	5.2	1,127	8,0	8.0	1,338	9,4	9,4
QC	176	2.1	2.1	185	2.2	2.2	149	1,8	1,8
NB	27	3.5	3.6	32	4.2	4,4	23	3.0	3.0
NS	40	4.2	4,4	58	6.1	6.3	49	5.1	5.3
PE	5	3,4	3.2	5	8'8	3.6	8	5.2	5,4
NL	13	2.5	2.6	23	4,4	4.7	10	1,9	1.9
YT	5	13.0	11.8	9	15.1	13,4	4	6'6	9.5
TN	4	0'6	10.3	1	2.2	1,9	2	4,4	3,8
NU	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Canada	2,470	6.8	6.8	3,555	2.6	8.6	3,914	10.6	10.6

		2019			2020			2021	
Province or territory	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population
BC	971	19.1	19.0	1,762	34.2	34.1	2,261	43.5	43,4
AB	619	14.2	13.9	1,167	26.4	26.2	1,618	36,4	36.0
SK	109	6'3	6'6	254	21.6	22.5	322	27.3	29.0
MB	54	3.9	4.0	249	18,0	18,6	264	19.0	19,3
NO	1,432	8'6	6'6	2,327	15.8	15,9	2,721	18,4	18.5
QC	161	1,9	1,9	229	2.7	2.7	450	5.2	5.3
NB	27	3.5	3,5	38	4.9	4.9	39	4.9	5.2
NS	45	4,6	4.8	42	4.3	4.5	34	3,4	3.5
PE	5	3.2	3,3	8	5.0	4.9	12	7.3	8.2
NL	13	2.5	2.5	18	3.5	3.8	22	4.2	4.6
YT	4	2'6	10.0	10	23.7	23.3	23	53.2	49,6
NT	0	0.0	0.0	3	9'9	5.8	4	8'8	8.0
NU	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Canada	3,440	9.1	9.2	6,107	16.1	16.3	7,770	20.3	20.6

		2022	
Province or territory	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population
BC	2,270	42.7	42.7
AB	1,492	32.8	32,4
SK	223	18.7	19.8
MB	51	3.6	2'8
NO	2,377	15.7	15.9
QC	541	6.2	6,3
NB	40	4,9	5'3
NS	49	4,8	4.9
PE	4	2.3	2:2
N	17	3.2	3,5
ΥT	19	43,4	40,4
NT	3	9'9	6.1
NU	Suppr.	Suppr.	Suppr.
Canada	7,086	18.2	18.5

Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules. Suppressed (Suppr.)

Not available (n/a) Data were not available at the time of this publication.

Includes deaths related to all illicit drugs including, but not limited to, opioids and stimulants.

Includes deaths related to all drug or opioid intoxications including, but not limited to, opioids and stimulants.

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

Table 2b. Number and rate (per 100,000 population) of accidental apparent stimulant toxicity deaths by province or territory, 2018 to 2022

		2018			2019			2020	
Province or territory	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population
BC	1,057	21.1	21.0	480	9,4	9,4	983	19.1	19.1
SK	77	9'9	6.8	93	7.9	8.2	181	15,4	16.0
MB	n/a	n/a	n/a	73	5.3	5.4	241	17.5	17.8
ON	885	6.2	6.2	066	6,8	6'9	1,688	11.5	11.6
QC	144	1.7	1.7	134	1,6	1,6	185	2.2	2.2
NS	23	2,4	2.5	27	2.8	2.8	32	3.3	3,4
NL	n/a	n/a	n/a	n/a	n/a	n/a	10	1,9	2.2
YT	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
NT	n/a	n/a	n/a	n/a	n/a	n/a	3	9'9	5.8

		2021			2022	
Province or territory	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population	Number	Crude rate per 100,000 population	Age-adjusted rates per 100,000 population
BC	711	13.7	13.7	186	3.5	3,5
SK	259	21.9	23.1	178	14.9	15.6
MB	275	19.8	20.3	50	3.5	3,6
NO	2,030	13.7	13.8	1,763	11.7	11.8
QC	n/a	n/a	n/a	n/a	n/a	n/a
NS	32	3.2	3,3	43	4.2	4.3
NL	15	2.9	3.1	14	2.7	2.8
YT	9	13.9	12.6	15	34.3	33.5
LN	3	9'9	6.1	8	9'9	6.1

Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules. Data were not available at the time of this publication. Suppressed (Suppr.) Not available (n/a)

Note(s):

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

Table 3a. Number and percentage of apparent opioid toxicity deaths in Canada by manner of death, 2016 to 2022

Manner of	2016	16	2017	17	2018	18	2019	19	2020	20	2021	21	2022	.2
death	Count	%												
Total	2,831	100%	3,924	100%	4,207	100%	3,713	100%	6,426	100%	8,013	100%	7,328	100%
Accidental	2,470	87%	3,555	91%	3,914	93%	3,440	93%	201′9	%26	0/2/2	%26	980′2	%26
Suicide	264	%6	277	%2	219	2%	200	2%	198	3%	113	1%	146	2%
Undetermined	26	3%	92	2%	74	2%	73	2%	121	2%	130	2%	96	1%

ote(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

Table 3b. Percentage of apparent stimulant toxicity deaths in Canada by manner of death, 2018 to 2022

Manner of death	2018	2019	2020	2021	2022
Total	100%	100%	100%	100%	100%
Accidental	%26	%96	%86	%86	%86
Suicide	2%	3%	1%	1%	1%
Undetermined	1%	1%	1%	1%	1%

Note(s):

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved. Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

Table 4a. Summary of total apparent opioid toxicity deaths in Canada, 2016 to 2022

		2016	2017	2018	2019	2020	2021	2022
	Number	2,831	3,924	4,207	3,713	6,426	8,013	7,328
Total	Crude rate	7.8	10.7	11,4	6'6	16.9	21.0	18,8
	Age-adjusted rate	7.8	10.8	11,4	10.0	17.1	21.3	19.1
4	Male	%02	74%	72%	71%	75%	73%	73%
rercent by sex	Female	30%	79%	78%	78%	72%	27%	27%
	0 to 19	2%	7%	5%	2%	%7	%7	2%
	20 to 29	18%	20%	20%	19%	18%	18%	15%
Percent by age	30 to 39	27%	27%	27%	78%	27%	78%	28%
group	40 to 49	21%	21%	21%	21%	23%	23%	25%
	50 to 59	22%	21%	21%	21%	21%	20%	20%
	60 or more	%6	%6	%6	10%	%01	%6	11%
	Fentanyl	52%	%69	%02	%09	81%	%28	%62
- + + + + + + + + + + + + + + + + + + +	Fentanyl analogues	n/a	n/a	%6	21%	13%	19%	20%
(categories not	Non fentanyl opioids	29%	39%	46%	44%	31%	72%	29%
mutually exclusive)	Stimulants	n/a	n/a	%95	25%	%£9	%49	25%
	Other psychoactive substances	%89	%09	44%	43%	44%	46%	45%

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

Table 4b. Summary of total apparent stimulant toxicity deaths in Canada, 2018 to 2022

		2018	2019	2020	2021	2022
Number of reporting provinces or territories	vinces or territories	Ŋ	9	8	8	8
	Male	%92	74%	%92	74%	75%
rercent by sex	Female	24%	26%	24%	26%	25%
	0 to 19	1%	1%	2%	1%	1%
	20 to 29	17%	18%	16%	17%	14%
	30 to 39	26%	28%	26%	28%	27%
rercein by age group	40 to 49	23%	22%	24%	24%	26%
	50 to 59	24%	21%	23%	21%	22%
	60 or more	%8	10%	%6	%6	10%
	Cocaine	%02	65%	%99	93%	64%
- to Co.	Methamphetamine	44%	46%	51%	54%	53%
(categories not	Other stimulants	7%	7%	14%	10%	2%
mutually exclusive)	Opioids	81%	75%	83%	82%	78%
	Other psychoactive substances	31%	78%	31%	78%	28%

Note(s):

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved. Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

Table 5a. Number of total apparent opioid toxicity deaths by quarter and province or territory, January 2016 to December 2022

Province or		2016	16			2017	17			2018	18	
territory	Δ	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
BC	176	157	153	320	353	364	317	262	355	315	363	321
AB	137	140	159	166	162	182	183	217	194	206	210	195
SK	25	17	24	17	25	20	22	18	34	28	34	30
MB	18	20	17	33	34	34	19	19	21	17	24	31
NO	214	218	195	240	238	311	414	302	316	332	405	454
QC	89	64	89	63	65	62	69	29	55	51	42	63
NB	12	4	10	80	10	8	8	12	8	4	6	6
NS	17	14	17	5	19	17	13	15	15	18	10	11
PE	n/a	n/a	n/a	n/a	Suppr.	Suppr.	Suppr.	0	0	Suppr.	Suppr.	Suppr.
NL	Suppr.	Suppr.	8	5	11	9	6	7	Suppr.	Suppr.	Suppr.	Suppr.
YT	0	2	2	က	4	0	1	2	0	0	3	2
NT	2	0	1	2	0	0	1	0	1	0	1	0
NU	Suppr.											
Canada	699	989	654	862	921	1,021	1,056	921	666	971	1,101	1,116

Province or		2019	19			2020	20			2021	21	
territory	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
BC	306	253	230	230	285	501	496	513	543	545	277	699
AB	162	187	152	125	161	318	359	347	361	361	402	502
SK	25	34	23	35	26	73	83	86	89	58	93	113
MB	10	16	11	25	26	56	96	82	89	74	71	22
NO	458	479	246	375	470	630	634	725	737	734	829	705
QC	54	55	51	51	56	80	6	98	66	113	127	111
NB	9	2	15	7	5	10	12	18	14	6	11	10
NS	14	18	13	12	6	12	10	19	12	8	9	13
PE	Suppr.	Suppr.	Suppr.	0	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	9	Suppr.
N	80	9	Suppr.	Suppr.	Suppr.	6	9	Suppr.	9	5	7	7
ΥT	1	0	0	3	3	3	3	1	5	2	5	80
NT	1	0	0	0	0	0	0	3	1	1	2	0
NO	Suppr.											
Canada	1,045	1,055	741	863	1,041	1,692	1,796	1,880	1,914	1,913	1,985	2,195

Province or		2022	22	
territory	Q1	Q2	Q3	Q4
BC	603	539	586	614
AB	452	353	309	385
SK	77	80	58	20
MB	52	n/a	n/a	n/a
NO	645	594	614	648
QC	116	136	144	145
NB	13	16	11	9
NS	23	11	16	12
PE	Suppr.	0	Suppr.	0
NL	Suppr.	6	12	Suppr.
ΥT	10	4	1	4
NT	2	1	0	0
NO	Suppr.	Suppr.	Suppr.	Suppr.
Canada	1,993	1,740	1,751	1,834

Data were not available at the time of this publication.

Includes deaths related to all illicit drugs including, but not limited to, opioids and stimulants.

includes deaths related to all drug or opioid intoxications including, but not limited to, opioids and stimulants.

Q1 = January to March; Q2 = April to June; Q3 = July to September; Q4 = October to December

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

 Table 5b.
 Number of total apparent stimulant toxicity deaths by quarter and province or territory, January 2018 to December 2022

Province or		2018	18			20	2019			2020	20	
territory	Q1	Q2	Q 3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
BC	277	247	288	256	82	87	156	173	185	324	232	252
SK	23	24	18	19	23	31	18	23	21	51	50	62
MB	n/a	n/a	n/a	n/a	15	23	16	27	29	53	84	83
NO	171	210	251	284	284	291	171	279	307	477	450	494
ОС	37	47	49	30	37	33	31	41	32	63	62	36
NS	4	8	7	9	9	8	7	5	7	10	7	11
NL	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Suppr.	9	0	Suppr.
ΥT	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
NT	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0	0	0	က

Province or		2021	121			2022	22	
territory	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
BC	221	168	167	161	96	41	32	17
SK	51	49	72	96	61	58	45	18
MB	67	83	73	58	50	n/a	n/a	n/a
NO	518	491	536	538	483	475	445	408
ОС	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
NS	8	10	9	10	12	12	11	10
NL	Suppr.	Suppr.	9	Suppr.	9	Suppr.	Suppr.	Suppr.
YT	3	1	0	2	5	4	2	4
NT	0	0	3	0	2	1	0	0

Not available (n/a) Data were not available at the time of this publication.

Q1 = January to March; Q2 = April to June; Q3 = July to September; Q4 = October to December

Note(s):

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Table 6a. Number of accidental apparent opioid toxicity deaths by quarter and province or territory, January 2016 to December 2022

Province or		2016	16			2017	17			2018	18	
territory	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
BC	170	157	147	316	349	359	308	258	355	311	356	318
AB	118	130	144	155	152	161	171	199	193	206	207	193
SK	25	14	22	15	22	11	19	16	31	25	30	28
MB	11	14	13	23	26	27	18	16	15	14	22	27
NO	174	180	174	198	191	276	380	280	267	298	366	407
QC	52	44	43	37	44	52	48	41	36	39	27	47
NB	11	3	9	2	8	9	7	11	2	4	5	7
NS	14	8	15	3	17	16	12	13	14	16	8	11
PE	n/a	n/a	n/a	n/a	Suppr.	Suppr.	Suppr.	0	0	Suppr.	Suppr.	Suppr.
NL	Suppr.	Suppr.	Suppr.	Suppr.	7	Suppr.	7	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
YT	0	2	0	3	3	0	1	2	0	0	2	2
NT	1	0	1	2	0	0	1	0	1	0	1	0
NU	Suppr.											
Canada	929	552	565	759	819	914	972	836	919	913	1,024	1,040

Province or		2019	19			20	2020			2021	21	
territory	Q1	Q2	Q3	Q4	QI	Q2	Q3	Q4	Q1	Q2	03	Q4
BC	293	245	213	220	277	493	488	504	534	529	555	643
AB	161	183	151	124	153	313	358	343	357	359	400	502
SK	23	33	22	31	24	89	18	81	64	22	92	111
MB	7	13	10	24	24	52	92	81	99	72	69	57
NO	422	452	219	339	442	009	265	688	703	701	929	661
QC	40	46	36	39	39	51	73	99	66	113	127	111
NB	5	6	11	5	4	6	6	16	12	8	6	10
NS	10	14	10	11	5	12	10	15	11	8	5	10
PE	Suppr.	Suppr.	Suppr.	0	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	9	Suppr.
NL	5	Suppr.	Suppr.	Suppr.	Suppr.	80	Suppr.	Suppr.	5	5	2	7
YT	1	0	0	8	က	8	8	1	5	5	2	80
NT	0	0	0	0	0	0	0	3	1	1	2	0
NU	Suppr.											
Canada	296	992	672	296	971	1,609	1,711	1,798	1,857	1,856	1,931	2,120

Province or		2022	22	
territory	Q1	Q2	Q3	Q4
ВС	929	525	267	602
AB	447	353	309	383
SK	71	92	22	19
MB	51	n/a	n/a	n/a
NO	614	565	581	617
QC	116	136	144	145
NB	10	14	10	9
NS	18	7	13	11
PE	Suppr.	0	Suppr.	0
NL	Suppr.	5	8	Suppr.
ΥT	10	4	1	4
NT	2	1	0	0
NU	Suppr.	Suppr.	Suppr.	Suppr.
Canada	1,915	1,686	1,690	1,787

Not available (n/a) Data were not available at the time of this publication.

Includes deaths related to all illicit drugs including, but not limited to, opioids and stimulants.

Includes deaths related to all drug or opioid intoxications including, but not limited to, opioids and stimulants.

Q1 = January to March; Q2 = April to June; Q3 = July to September; Q4 = October to December

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Table 6b. Number of accidental apparent stimulant toxicity deaths by quarter and province or territory, January 2018 to December 2022

Province or		2018	18			2019	19			2020	20	
territory	Q1	Q2	Q 3	Q4	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
BC	276	246	281	254	22	85	150	168	183	321	230	249
SK	23	20	15	19	22	30	18	23	19	50	50	62
MB	n/a	n/a	n/a	n/a	12	21	14	26	27	50	82	82
NO	168	203	242	272	273	281	166	270	867	465	440	485
dc	31	43	43	27	34	33	29	38	31	58	09	36
NS	4	7	9	9	6	8	9	4	2	10	7	10
NL	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	Suppr.	9	0	Suppr.
YT	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
NT	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0	0	0	3

Province or		2021	21			20	2022	
territory	Q1	Q2	Q3	Q4	Q1	Q2	Q3	Q4
BC	220	166	164	161	96	40	33	17
SK	47	49	69	94	60	57	45	16
MB	99	81	71	58	50	n/a	n/a	n/a
NO	504	473	526	527	469	465	432	397
dc	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
NS	8	10	5	6	11	11	11	10
NL	Suppr.	Suppr.	5	Suppr.	9	Suppr.	Suppr.	Suppr.
YT	3	1	0	2	5	4	2	4
LN	0	0	က	0	2	1	0	0

Not available (n/a) Data were not available at the time of this publication.

Q1 = January to March; Q2 = April to June; Q3 = July to September; Q4 = October to December

Note(s):

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Table 7a. Percentage of accidental apparent opioid toxicity deaths by sex and province or territory, 2016 to 2022

Province or	20	2016	201	41	2018	8	2019	19	20	2020	20	2021	20	2022
territory	Male	Female												
BC	%08	20%	82%	18%	%08	20%	%9/	24%	82%	18%	%8/	22%	%83%	17%
AB	73%	27%	%92	24%	74%	26%	74%	26%	77%	23%	73%	27%	73%	27%
SK	%69	41%	21%	43%	%69	41%	64%	36%	%99	34%	%99	34%	62%	38%
MB	%19	39%	%29	33%	22%	45%	%69	31%	63%	37%	64%	36%	%/9	33%
NO	%12	78%	75%	72%	73%	27%	72%	78%	%//	73%	%4/	79%	%9/	25%
ОС	%89	32%	%69	31%	%89	37%	%89	32%	%02	%08	%8/	22%	%62	21%
NB	63%	37%	29%	41%	43%	21%	48%	52%	25%	45%	29%	41%	%29	35%
NS	78%	23%	71%	79%	%29	33%	71%	29%	%69	31%	74%	26%	%69	31%
PE	Suppr.													
NL	62%	38%	%02	30%	20%	20%	Suppr.	Suppr.	Suppr.	Suppr.	%89	32%	29%	41%
YT	Suppr.	61%	39%	47%	53%									
NT	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	%0	%0	Suppr.	Suppr.	75%	25%	67%	33%
NU	Suppr.													
Canada	74%	26%	%22	23%	74%	79%	72%	28%	%92	24%	74%	26%	74%	26%

Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules. Data were not available at the time of this publication. Suppressed (Suppr.)

Not available (n/a)

includes deaths related to all drug or opioid intoxications including, but not limited to, opioids and stimulants.

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

Table 7b. Percentage of accidental apparent stimulant toxicity deaths by sex and province or territory, 2018 to 2022

Province or	20	2018	20	2019	20	2020	2021	21	20	2022
territory	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
BC	%62	21%	75%	25%	%08	20%	%92	24%	84%	16%
SK	%89	42%	65%	35%	%29	33%	%29	33%	%99	34%
MB	n/a	n/a	75%	25%	%89	37%	%99	34%	64%	36%
NO	74%	76%	74%	26%	%9/	24%	75%	25%	%92	24%
QC	%82	22%	75%	25%	%//	73%	n/a	n/a	n/a	n/a
NS	74%	26%	85%	15%	81%	19%	72%	28%	81%	19%
NL	n/a	n/a	n/a	n/a	Suppr.	Suppr	Suppr.	Suppr.	Suppr.	Suppr.
YT	n/a	n/a	n/a	n/a	n/a	n/a	Suppr.	Suppr.	Suppr.	Suppr.
NT	n/a	n/a	n/a	n/a	Suppr.	Suppr.	%29	33%	%29	33%
Canada	%92	24%	74%	26%	%92	24%	74%	79%	%92	24%

Not available (n/a) Data were not available at the time of this publication.

Jote(s):

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved. Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

Table 8a. Crude rate (per 100,000 population) of accidental apparent opioid toxicity deaths by sex and province or territory, 2016 to 2022

Province or	20	2016	201	17	20	2018	20	2019	2020	20	20	2021	2022	22
territory	Male	Female												
BC	26.4	6.3	43.1	0'6	43.4	10,4	17.0	5,4	39,1	8,4	26.3	7.1	2'3	1.5
AB	18,9	7.1	24.3	7.8	27.3	8'6	20,8	2'2	40.3	12.3	53,1	19.6	47.6	17.9
SK	6'2	5,5	7.2	5,6	11.4	8,2	11.8	6.7	28,3	14.7	35,5	18,9	23,1	14.2
MB	5.6	3,6	8.7	4,3	6.4	5.2	5,4	2,5	22.8	13,3	24.2	13.8	4,8	2.4
NO	7.5	3.0	12.1	4.0	13.7	5.1	14.4	5,4	24.5	7.3	27.6	9,3	53.9	7.7
QC	2.9	1,4	3.1	1,4	2.2	1,3	2.6	1.2	3.7	1.6	8.2	2.3	8'6	2.6
NB	4.5	2.6	2.0	3,4	2.6	3,3	3,4	3,6	5,4	4.3	5.9	4.0	6.4	3.4
NS	2'9	1.9	8'8	3,5	7.0	3,3	6.7	2,6	0'9	2,6	5.1	1,8	8'9	2.9
PE	Suppr.													
NL	3.0	1.9	6.1	2.6	1.9	1.9	Suppr.	Suppr.	Suppr.	Suppr.	5,8	2.7	3,8	2.6
YT	Suppr.	63.7	42.3	40.5	46.3									
NT	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	0'0	0'0	Suppr.	Suppr.	12,8	4.5	8,5	4.5
NU	Suppr.													
Canada	10.1	3,6	15.0	4.5	15.7	5.4	11.7	4.4	22.3	6'9	24.7	8.6	19.3	9'9

Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules. Data were not available at the time of this publication. Suppressed (Suppr.) Not available (n/a)

includes deaths related to all drug or opioid intoxications including, but not limited to, opioids and stimulants.

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

Table 8b. Crude rate (per 100,000 population) of accidental apparent stimulant toxicity deaths by sex and province or territory, 2018 to 2022

Province or	2018	18	20	2019	2020	20	2021	21	2022	22
territory	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
BC	33.8	8,6	14.2	4.7	31.0	7.4	21.0	6.5	5.9	1.1
SK	7.7	5.6	10.2	2.7	20.4	10.3	29.1	14.7	19,3	10.3
MB	n/a	n/a	8.0	2.6	21.9	13.0	26.2	13,4	4.5	2.6
NO	9.2	3.2	10.3	3,4	17.7	5.3	20.8	6.8	17.9	5.5
QC	2.7	0.7	2,4	0,8	3,3	1.0	n/a	n/a	n/a	n/a
NS	3.6	1.2	4.8	0,8	5.4	1.2	4.7	1.8	7.0	1.5
NL	n/a	n/a	n/a	n/a	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
YT	n/a	n/a	n/a	n/a	n/a	n/a	Suppr.	Suppr.	Suppr.	Suppr.
NT	n/a	n/a	n/a	n/a	Suppr.	Suppr.	8.5	4.5	8.5	4.5

Not available (n/a) Data were not available at the time of this publication.

Note(s):

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved. Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

Table 9a. Percentage of accidental apparent opioid toxicity deaths by age group and province or territory, 2016 to 2022

Province or			Age	group		
territory	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
ВС	3%	21%	28%	23%	21%	5%
AB	2%	21%	37%	18%	17%	5%
SK	0%	12%	45%	13%	21%	9%
MB	5%	30%	26%	16%	15%	8%
ON	2%	19%	24%	22%	25%	8%
QC	2%	14%	19%	26%	28%	12%
NB	0%	11%	22%	30%	26%	11%
NS	3%	20%	30%	13%	23%	13%
PE	0%	0%	0%	Suppr.	Suppr.	Suppr.
NL	0%	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
YT	0%	Suppr.	Suppr.	Suppr.	Suppr.	0%
NT	0%	50%	0%	0%	25%	25%
NU	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Canada	2%	20%	28%	21%	22%	7%

Province or			Age	group		
territory	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
ВС	2%	19%	28%	23%	21%	7%
AB	3%	24%	32%	19%	17%	5%
SK	4%	28%	23%	20%	16%	8%
MB	0%	31%	32%	22%	7%	8%
ON	2%	21%	27%	22%	20%	8%
QC	2%	15%	24%	19%	27%	14%
NB	3%	22%	28%	19%	19%	9%
NS	5%	10%	26%	24%	29%	5%
PE	0%	Suppr.	Suppr.	Suppr.	Suppr.	0%
NL	0%	22%	39%	35%	Suppr.	Suppr.
YT	0%	Suppr.	Suppr.	Suppr.	0%	0%
NT	0%	0%	Suppr.	0%	0%	Suppr.
NU	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Canada	2%	21%	28%	21%	20%	7%

Province or			Age	group		
territory	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
ВС	2%	19%	27%	22%	22%	8%
AB	2%	25%	30%	20%	18%	7%
SK	0%	24%	25%	20%	20%	11%
MB	0%	26%	28%	20%	20%	7%
ON	2%	20%	29%	22%	20%	8%
QC	1%	13%	28%	22%	23%	13%
NB	0%	9%	22%	22%	35%	13%
NS	2%	22%	24%	20%	18%	12%
PE	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
NL	0%	0%	Suppr.	80%	Suppr.	0%
YT	0%	Suppr.	Suppr.	0%	Suppr.	0%
NT	50%	50%	0%	0%	0%	0%
NU	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Canada	2%	20%	28%	21%	21%	8%

Province or			Age (group		
territory	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
ВС	2%	18%	29%	22%	20%	9%
AB	2%	23%	31%	21%	18%	5%
SK	1%	19%	23%	24%	28%	6%
MB	2%	28%	31%	17%	19%	4%
ON	1%	20%	29%	19%	22%	8%
QC	2%	12%	17%	27%	25%	17%
NB	0%	7%	30%	19%	22%	22%
NS	2%	16%	22%	27%	18%	16%
PE	0%	Suppr.	Suppr.	0%	Suppr.	Suppr.
NL	0%	Suppr.	Suppr.	38%	0%	Suppr.
YT	0%	0%	0%	Suppr.	Suppr.	Suppr.
NT	0%	0%	0%	0%	0%	0%
NU	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Canada	2%	20%	28%	21%	21%	8%

Province or			Age	group		
territory	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
ВС	2%	17%	24%	24%	24%	10%
AB	2%	20%	29%	23%	19%	7%
SK	3%	20%	29%	20%	19%	9%
МВ	1%	19%	31%	28%	14%	6%
ON	1%	19%	29%	23%	20%	8%
QC	3%	16%	26%	17%	20%	17%
NB	0%	13%	16%	29%	24%	18%
NS	0%	24%	21%	36%	12%	7%
PE	0%	Suppr.	0%	Suppr.	0%	Suppr.
NL	Suppr.	Suppr.	44%	Suppr.	28%	0%
YT	0%	50%	Suppr.	Suppr.	Suppr.	0%
NT	0%	33%	67%	0%	0%	0%
NU	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Canada	2%	18%	28%	23%	20%	8%

Province or			Age	group		
territory	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
ВС	1%	15%	25%	21%	26%	12%
AB	2%	19%	32%	22%	17%	7%
SK	1%	23%	23%	26%	20%	7%
MB	2%	20%	37%	21%	14%	5%
ON	2%	18%	29%	23%	20%	8%
QC	2%	11%	25%	24%	22%	16%
NB	0%	15%	21%	38%	13%	13%
NS	0%	26%	24%	18%	21%	12%
PE	0%	0%	50%	Suppr.	Suppr.	0%
NL	0%	Suppr.	41%	27%	Suppr.	Suppr.
YT	0%	Suppr.	35%	35%	Suppr.	Suppr.
NT	0%	0%	50%	50%	0%	0%
NU	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Canada	2%	18%	29%	23%	20%	9%

Province or			Age (group		
territory	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
ВС	1%	13%	28%	26%	22%	9%
AB	2%	18%	31%	24%	15%	8%
SK	2%	17%	26%	31%	18%	6%
МВ	4%	22%	27%	31%	12%	4%
ON	1%	15%	29%	25%	21%	10%
QC	2%	10%	18%	24%	26%	20%
NB	3%	25%	20%	23%	25%	5%
NS	2%	14%	18%	24%	24%	16%
PE	0%	Suppr.	Suppr.	0%	0%	Suppr.
NL	0%	Suppr.	29%	29%	Suppr.	Suppr.
YT	0%	32%	47%	Suppr.	Suppr.	0%
NT	0%	0%	33%	67%	0%	0%
NU	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Canada	2%	16%	28%	25%	20%	10%

Not available (n/a)

Suppressed (Suppr.) Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules. Data were not available at the time of this publication.

Includes deaths related to all drug or opioid intoxications including, but not limited to, opioids and stimulants.

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Table 9b. Percentage of accidental apparent stimulant toxicity deaths by age group and province or territory, 2018 to 2022

Province or			Age (group		
territory	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
ВС	1%	16%	25%	23%	25%	9%
SK	1%	21%	32%	27%	13%	5%
МВ	n/a	n/a	n/a	n/a	n/a	n/a
ON	1%	17%	29%	24%	22%	7%
QC	2%	17%	15%	22%	30%	15%
NS	4%	35%	22%	13%	22%	4%
NL	n/a	n/a	n/a	n/a	n/a	n/a
YT	n/a	n/a	n/a	n/a	n/a	n/a
NT	n/a	n/a	n/a	n/a	n/a	n/a
Canada	1%	17%	26%	23%	24%	8%

Province or			Age (group		
territory	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
BC	2%	16%	26%	23%	21%	11%
SK	1%	22%	37%	19%	16%	5%
MB	1%	25%	32%	29%	12%	1%
ON	1%	17%	28%	22%	22%	9%
QC	3%	15%	19%	19%	28%	16%
NS	4%	15%	26%	19%	19%	19%
NL	n/a	n/a	n/a	n/a	n/a	n/a
YT	n/a	n/a	n/a	n/a	n/a	n/a
NT	n/a	n/a	n/a	n/a	n/a	n/a
Canada	2%	17%	28%	22%	22%	10%

Province or			Age (group		
territory	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
ВС	1%	15%	23%	25%	25%	11%
SK	2%	18%	34%	21%	19%	6%
MB	3%	21%	33%	27%	13%	5%
ON	1%	16%	29%	23%	23%	8%
QC	2%	8%	17%	24%	35%	14%
NS	3%	22%	19%	22%	22%	13%
NL	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	0%
YT	n/a	n/a	n/a	n/a	n/a	n/a
NT	0%	33%	67%	0%	0%	0%
Canada	2%	16%	27%	24%	23%	9%

Province or			Age (group		
territory	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
ВС	1%	13%	23%	23%	27%	12%
SK	2%	24%	29%	23%	18%	4%
MB	2%	19%	35%	22%	15%	7%
ON	1%	17%	29%	24%	20%	9%
QC	n/a	n/a	n/a	n/a	n/a	n/a
NS	0%	34%	28%	9%	19%	9%
NL	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
YT	0%	Suppr.	Suppr.	Suppr.	0%	Suppr.
NT	0%	0%	33%	67%	0%	0%
Canada	1%	17%	28%	24%	21%	9%

Province or			Age (group		
territory	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
ВС	0%	12%	28%	28%	23%	9%
SK	2%	18%	26%	33%	15%	7%
MB	4%	20%	30%	28%	12%	6%
ON	1%	14%	27%	25%	22%	10%
QC	n/a	n/a	n/a	n/a	n/a	n/a
NS	0%	19%	19%	26%	19%	19%
NL	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
YT	0%	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
NT	0%	0%	33%	67%	0%	0%
Canada	1%	14%	27%	26%	22%	10%

Suppressed (Suppr.) Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules.

Not available (n/a) Data were not available at the time of this publication.

Note(s):

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Table 10a. Percentage of accidental apparent opioid toxicity deaths by type of opioids and province or territory, 2016 to 2022

Province or		2016			2017			2018	
territory	Fentanyl	Analogues	Non-fentanyl	Fentanyl	Analogue	Non-fentanyl	Fentanyl	Analogues	Non-fentanyl
BC	%08	3%	92%	91%	11%	29%	94%	2%	39%
AB	%89	n/a	37%	81%	n/a	19%	72%	20%	28%
SK	11%	n/a	%68	20%	n/a	80%	41%	4%	%89
MB	46%	n/a	54%	51%	n/a	49%	38%	n/a	62%
NO	45%	n/a	%29	%69	n/a	31%	%02	%6	44%
QC	24%	n/a	%88	78%	n/a	95%	18%	%9	93%
NB	15%	n/a	%86	22%	n/a	91%	4%	n/a	100%
NS	18%	n/a	83%	10%	n/a	%06	16%	%8	%96
PE	20%	n/a	%08	%0	n/a	100%	13%	n/a	%88
NL	Suppr.	n/a	95%	26%	n/a	74%	%0	n/a	100%
YT	%08	n/a	20%	83%	n/a	17%	100%	n/a	%0
LN	72%	n/a	%9/	%0	n/a	100%	%0	n/a	100%
NU	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Canada	21%	n/a	25%	74%	n/a	35%	74%	10%	43%

Province or		2019			2020			2021	
territory	Fentanyl	Analogues	Non-fentanyl	Fentanyl	Analogue	Non-fentanyl	Fentanyl	Analogues	Non-fentanyl
BC	%68	12%	33%	95%	36%	22%	95%	79%	21%
AB	77%	10%	30%	87%	10%	20%	%68	79%	15%
SK	37%	11%	71%	63%	21%	20%	%98	%29	30%
MB	29%	11%	54%	81%	2%	20%	84%	54%	42%
NO	26%	35%	37%	88%	2%	24%	%06	2%	21%
QC	17%	1%	93%	30%	3%	83%	43%	%2	%92
NB	19%	n/a	%68	11%	n/a	%68	13%	2%	95%
NS	%6	2%	%96	24%	%/_	%98	18%	%6	%9/
PE	%0	n/a	100%	20%	%0	20%	%0	%0	100%
NL	Suppr.	n/a	85%	Suppr.	Suppr.	78%	27%	%0	%22
YT	75%	n/a	25%	80%	%0	20%	100%	48%	4%
NT	%0	%0	%0	100%	%0	%0	%09	%0	75%
NO	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Canada	63%	22%	41%	84%	14%	78%	87%	19%	24%

Province or		2021	
territory	Fentanyl	Analogues	Non-fentanyl
BC	95%	23%	21%
AB	%98	34%	16%
SK	%22	%69	30%
MB	%06	%88	%89
NO	85%	%6	23%
ac	40%	2%	%92
NB	39%	21%	92%
NS	12%	%9	95%
PE	%0	%0	100%
NL	Suppr.	%0	94%
ΥT	95%	%0	2%
TN	100%	100%	%0
NU	Suppr.	Suppr.	Suppr.
Canada	81%	20%	27%

Not available (n/a) Data were not available at the time of this publication.

Includes deaths related to all drug or opioid intoxications including, but not limited to, opioids and stimulants.

Analogue = Fentanyl analogues; Non-fentanyl = Non-fentanyl opioids

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Until investigations are completed, some provinces and territories report fentanyl information only or report data on fentanyl and fentanyl analogues together. Therefore, some deaths involving fentanyl analogues may be included in the fentanyl percentages.

Table 10b. Percentage of accidental apparent stimulant toxicity deaths by type of stimulants and province or territory, 2018 to 2022

Province or		2018			2019			2020	
territory	Cocaine	Meth	Other stimulants	Cocaine	Meth	Other stimulants	Cocaine	Meth	Other stimulants
BC	%89	20%	3%	61%	54%	3%	%09	%69	%9
SK	51%	92%	14%	25%	%//	%6	31%	72%	%9
MB	n/a	n/a	n/a	92%	29%	2%	%89	%89	81%
NO	75%	36%	2%	73%	39%	4%	73%	43%	%9
dc	978	n/a	38%	61%	n/a	39%	%29	n/a	43%
NS	91%	13%	%6	%29	33%	15%	84%	%0	22%
NL	n/a	n/a	n/a	n/a	n/a	n/a	Suppr.	Suppr.	%09
YT	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
NT	n/a	n/a	n/a	n/a	n/a	n/a	100%	%0	%0
Canada	%02	44%	%2	%59	46%	%2	%99	51%	13%

Province or		2021			2022	
territory	Cocaine	Meth	Other stimulants	Cocaine	Meth	Other stimulants
BC	29%	28%	3%	54%	%19	%8
SK	18%	86%	4%	22%	%58	1%
MB	73%	62%	78%	72%	%89	84%
NO	%89	49%	3%	%89	%09	5%
ОС	n/a	n/a	n/a	n/a	n/a	n/a
NS	94%	28%	3%	88%	14%	16%
NL	%09	33%	%29	93%	Suppr.	36%
YT	100%	0%	%0	100%	%0	%2
NT	%29	%0	33%	100%	%0	%0
Canada	63%	54%	10%	64%	23%	2%

Not available (n/a) Data were not available at the time of this publication.

methamphetamine

Note(s):

Meth:

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

Table 11a. Percentage of accidental apparent opioid toxicity deaths involving stimulants, by province or territory, 2018 to 2022

Province or			Year		
territory	2018	2019	2020	2021	2022
ВС	72%	75%	71%	73%	70%
AB	57%	60%	67%	67%	44%
SK	44%	50%	60%	65%	67%
MB	n/a	59%	81%	86%	91%
ON	47%	51%	59%	61%	62%
QC	n/a	n/a	n/a	n/a	n/a
NB	n/a	n/a	n/a	n/a	n/a
NS	31%	38%	38%	50%	51%
PE	n/a	n/a	n/a	17%	0%
NL	n/a	n/a	44%	36%	41%
YT	n/a	n/a	n/a	26%	53%
NT	n/a	n/a	100%	50%	100%
NU	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Canada	58%	58%	64%	65%	56%

Suppressed (Suppr.) Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules.

Not available (n/a) Data were not available at the time of this publication.

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Table 11b. Percentage of accidental apparent stimulant toxicity deaths involving opioids, by province or territory, 2018 to 2022

Province or			Year		
territory	2018	2019	2020	2021	2022
ВС	91%	89%	88%	89%	88%
SK	65%	58%	84%	80%	84%
MB	n/a	44%	83%	83%	91%
ON	72%	74%	81%	81%	77%
QC	n/a	n/a	n/a	n/a	n/a
NS	65%	63%	50%	53%	58%
NL	n/a	n/a	80%	53%	50%
YT	n/a	n/a	n/a	100%	67%
NT	n/a	n/a	100%	67%	100%
Canada	81%	76%	83%	82%	78%

Suppressed (Suppr.) Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules.

Not available (n/a) Data were not available at the time of this publication.

Note(s):

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Table 12a. Percentage of accidental apparent opioid toxicity deaths involving other psychoactive substances, by province or territory, 2016 to 2022

Province or				Year			
territory	2016	2017	2018	2019	2020	2021	2022
ВС	31%	33%	35%	42%	44%	50%	53%
AB	65%	72%	73%	77%	81%	82%	76%
SK	95%	91%	43%	52%	50%	74%	71%
MB	95%	99%	51%	34%	69%	61%	92%
ON	93%	66%	23%	19%	17%	17%	24%
QC	80%	83%	88%	84%	84%	52%	50%
NB	93%	100%	100%	100%	97%	97%	100%
NS	90%	83%	84%	84%	81%	76%	63%
PE	100%	100%	88%	100%	88%	58%	25%
NL	100%	91%	100%	100%	44%	59%	82%
YT	100%	100%	100%	75%	20%	70%	58%
NT	75%	100%	100%	0%	100%	50%	0%
NU	Suppr.						
Canada	66%	59%	43%	42%	44%	46%	45%

Not available (n/a)

Suppressed (Suppr.) Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules. Data were not available at the time of this publication.

Includes deaths related to all drug or opioid intoxications including, but not limited to, opioids and stimulants.

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Table 12b. Percentage of accidental apparent stimulant toxicity deaths involving other psychoactive substances, by province or territory, 2018 to 2022

Province or			Year		
territory	2018	2019	2020	2021	2022
ВС	32%	38%	39%	44%	46%
SK	43%	39%	41%	64%	60%
MB	n/a	27%	66%	59%	92%
ON	16%	15%	13%	14%	19%
QC	86%	80%	79%	n/a	n/a
NS	65%	59%	56%	47%	49%
NL	n/a	n/a	Suppr.	53%	71%
YT	n/a	n/a	n/a	67%	50%
NT	n/a	n/a	100%	100%	0%
Canada	30%	28%	30%	29%	27%

Suppressed (Suppr.) Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules.

Not available (n/a) Data were not available at the time of this publication.

Note(s):

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Table 13. Percentage of accidental apparent opioid toxicity deaths by origin of opioid(s), by province or territory, 2018 to 2022

Dunning of		Ori	gin	
Province or territory	Pharmaceutical only	Non-pharmaceutical only*	Both	Undetermined
ВС	0%	61%	0%	39%
AB	16%	78%	1%	5%
SK	58%	35%	4%	3%
MB	n/a	n/a	n/a	n/a
ON	23%	65%	9%	3%
QC	n/a	n/a	n/a	n/a
NB	96%	0%	4%	0%
NS	85%	6%	8%	0%
PE	n/a	n/a	n/a	n/a
NL	100%	0%	0%	0%
YT	n/a	n/a	n/a	n/a
NT	n/a	n/a	n/a	n/a
NU	n/a	n/a	n/a	n/a
Canada	24%	66%	6%	3%

Province or territory	Origin				
	Pharmaceutical only	Non-pharmaceutical only*	Both	Undetermined	
ВС	0%	66%	0%	33%	
AB	16%	77%	0%	6%	
SK	60%	31%	5%	5%	
MB	39%	52%	4%	6%	
ON	18%	68%	11%	2%	
QC	n/a	n/a	n/a	n/a	
NB	81%	11%	4%	4%	
NS	93%	5%	2%	0%	
PE	n/a	n/a	n/a	n/a	
NL	77%	Suppr.	0%	Suppr.	
YT	n/a	n/a	n/a	n/a	
NT	n/a	n/a	n/a	n/a	
NU	n/a	n/a	n/a	n/a	
Canada	22%	67%	8%	4%	

Province or territory	Origin				
	Pharmaceutical only	Non-pharmaceutical only*	Both	Undetermined	
ВС	0%	78%	0%	22%	
AB	10%	84%	1%	6%	
SK	32%	53%	9%	7%	
MB	7%	43%	2%	48%	
ON	10%	78%	10%	1%	
QC	n/a	n/a	n/a	n/a	
NB	81%	11%	0%	8%	
NS	79%	13%	8%	0%	
PE	n/a	n/a	n/a	n/a	
NL	83%	Suppr.	0%	Suppr.	
YT	n/a	n/a	n/a	n/a	
NT	n/a	n/a	n/a	n/a	
NU	n/a	n/a	n/a	n/a	
Canada	13%	74%	7%	6%	

B		Ori	gin	
Province or territory	Pharmaceutical only	Non-pharmaceutical only*	Both	Undetermined
ВС	0%	79%	0%	21%
AB	5%	88%	0%	7%
SK	13%	71%	13%	3%
MB	0%	82%	0%	17%
ON	7%	81%	11%	2%
QC	n/a	n/a	n/a	n/a
NB	81%	8%	5%	5%
NS	75%	25%	0%	0%
PE	58%	0%	0%	42%
NL	Suppr.	Suppr.	0%	86%
YT	n/a	n/a	n/a	n/a
NT	50%	50%	0%	0%
NU	n/a	n/a	n/a	n/a
Canada	7%	81%	7%	5%

D		Ori	gin	
Province or territory	Pharmaceutical only	Non-pharmaceutical only*	Both	Undetermined
ВС	0%	79%	0%	21%
AB	6%	86%	0%	8%
SK	19%	70%	10%	1%
MB	0%	63%	0%	37%
ON	10%	80%	8%	2%
QC	n/a	n/a	n/a	n/a
NB	53%	47%	0%	0%
NS	74%	19%	7%	0%
PE	0%	0%	0%	100%
NL	Suppr.	Suppr.	0%	94%
YT	n/a	n/a	n/a	n/a
NT	0%	0%	0%	0%
NU	n/a	n/a	n/a	n/a
Canada	10%	79%	5%	6%

^{*} Includes deaths with suspected non-pharmaceutical fentanyl alone or with any other non-pharmaceutical opioid(s). Only applies to deaths with completed investigations.

Suppressed (Suppr.) Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules.

Not available (n/a) Data were not available at the time of this publication.

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants. 2022 data from Manitoba are based on January to March.

Table 14a. Number of accidental apparent opioid toxicity deaths by sex and age group, by province or territory, 2018 to 2022

Province or	0			Age	group		
territory	Sex	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
DO.	Female	4	57	76	53	52	22
BC	Male	20	200	281	239	248	88
AD	Female	9	51	55	46	36	12
AB	Male	6	146	181	112	105	40
OV	Female	0	11	12	8	13	3
SK	Male	0	16	16	15	10	10
MD	Female	n/a	n/a	n/a	n/a	n/a	n/a
MB	Male	n/a	n/a	n/a	n/a	n/a	n/a
ON	Female	7	77	106	75	70	32
ON	Male	14	187	280	217	204	69
00	Female	0	5	9	13	16	12
QC	Male	1	15	32	20	19	7
ND	Female	0	2	3	1	5	2
NB	Male	0	0	2	4	3	1
NO	Female	Suppr.	3	5	4	1	Suppr.
NS	Male	Suppr.	8	7	6	8	Suppr.
DE	Female	n/a	n/a	n/a	n/a	n/a	n/a
PE	Male	n/a	n/a	n/a	n/a	n/a	n/a
NII	Female	n/a	n/a	n/a	n/a	n/a	n/a
NL	Male	n/a	n/a	n/a	n/a	n/a	n/a
VT	Female	n/a	n/a	n/a	n/a	n/a	n/a
YT	Male	n/a	n/a	n/a	n/a	n/a	n/a
NT	Female	n/a	n/a	n/a	n/a	n/a	n/a
INI	Male	n/a	n/a	n/a	n/a	n/a	n/a
NU	Female	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
INU	Male	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
Conoda	Female	20	206	266	200	193	83
Canada	Male	41	572	799	613	597	215

Province or	Cov			Age	group		
territory	Sex	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
ВС	Female	9	22	42	27	31	8
BC	Male	5	82	123	96	80	43
AD	Female	7	40	45	28	33	10
AB	Male	6	100	147	100	79	24
OV	Female	0	8	7	12	11	1
SK	Male	1	13	18	14	19	5
MD	Female	1	4	5	2	4	1
MB	Male	0	11	12	7	6	1
ON	Female	6	77	116	70	103	25
ON	Male	15	215	299	207	210	89
0.0	Female	1	0	6	12	20	12
QC	Male	2	19	21	32	20	16
N.D.	Female	0	1	4	1	5	3
NB	Male	0	1	4	4	1	3
	Female	Suppr.	0	4	3	3	Suppr.
NS	Male	Suppr.	7	6	9	5	Suppr.
5.5	Female	n/a	n/a	n/a	n/a	n/a	n/a
PE	Male	n/a	n/a	n/a	n/a	n/a	n/a
	Female	n/a	n/a	n/a	n/a	n/a	n/a
NL	Male	n/a	n/a	n/a	n/a	n/a	n/a
VT	Female	n/a	n/a	n/a	n/a	n/a	n/a
YT	Male	n/a	n/a	n/a	n/a	n/a	n/a
NIT	Female	n/a	n/a	n/a	n/a	n/a	n/a
NT	Male	n/a	n/a	n/a	n/a	n/a	n/a
All I	Female	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
NU	Male	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
0	Female	24	152	229	155	210	60
Canada	Male	29	448	630	469	420	181

Province or	C	Age group							
territory	Sex	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more		
DC.	Female	7	38	56	50	48	21		
BC	Male	14	168	236	240	239	100		
AD	Female	7	58	70	71	52	13		
AB	Male	16	171	263	203	172	71		
01/	Female	4	19	21	16	18	8		
SK	Male	3	33	52	36	30	14		
MD	Female	3	21	25	24	12	6		
MB	Male	0	27	53	45	23	9		
ONL	Female	11	103	165	128	98	40		
ON	Male	22	329	517	399	378	137		
0.0	Female	1	7	20	16	11	14		
QC	Male	6	30	40	24	35	25		
N.D.	Female	0	3	4	4	3	3		
NB	Male	0	2	2	7	6	4		
	Female	Suppr.	2	3	5	1	Suppr.		
NS	Male	Suppr.	8	6	10	4	Suppr.		
	Female	0	Suppr.	0	Suppr.	0	Suppr.		
PE	Male	0	Suppr.	0	Suppr.	0	Suppr.		
	Female	Suppr.	Suppr.	Suppr.	Suppr.	52 172 18 30 12 23 98 378 11 35 3 6 1 4	0		
NL	Male	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	0		
\ (T	Female	0	Suppr.	Suppr.	Suppr.	Suppr.	0		
YT	Male	0	Suppr.	Suppr.	Suppr.	Suppr.	0		
	Female	0	0	0	0	0	0		
NT	Male	0	1	2	0	0	0		
	Female	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.		
NU	Male	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.		
	Female	33	251	364	314		105		
Canada	Male	61	769	1,171	964	887	360		

Province or	- Cov			Age	group		
territory	Sex	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
DC.	Female	6	40	46	35	51	9
BC	Male	6	89	169	149	172	91
A.D.	Female	10	100	159	84	56	24
AB	Male	22	211	362	272	227	91
CIZ	Female	3	36	27	23	15	7
SK	Male	1	37	46	61	49	17
MD	Female	3	22	36	16	13	5
MB	Male	2	31	62	39	25	9
ONL	Female	14	147	212	149	126	45
ON	Male	29	346	584	475	406	183
0.0	Female	Suppr.	12	24	25	22	Suppr.
QC	Male	Suppr.	37	89	82	78	Suppr.
ND	Female	0	2	4	8	2	0
NB	Male	0	4	4	7	3	5
NO	Female	Suppr.	2	2	3	1	Suppr.
NS	Male	Suppr.	7	6	3	6	Suppr.
55	Female	0	0	Suppr.	Suppr.	Suppr.	0
PE	Male	0	0	Suppr.	Suppr.	Suppr.	0
N.I.	Female Male Female Female	0	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
NL	Male	0	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
\/T	Female	0	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
YT	Male	0	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
NIT	Female	0	0	0	Suppr.	0	Suppr.
NT	Male	0	0	2	Suppr.	0	Suppr.
All	Female	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
NU	Male	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
0	Female	36	361	510	343	286	90
Canada	Male	60	762	1,324	1,088	966	396

Province or	Con			Age	group		
territory	Sex	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
ВС	Female	0	10	14	6	8	2
BC	Male	3	21	52	54	43	19
AD	Female	21	92	115	90	68	19
AB	Male	15	177	354	275	163	103
OIZ	Female	3	15	27	21	13	5
SK	Male	2	23	30	49	27	8
MD	Female	0	5	6	5	1	0
MB	Male	2	6	8	11	5	2
ON	Female	6	105	167	134	122	49
ON	Male	23	250	515	446	367	176
0.0	Female	Suppr.	12	25	24	26	Suppr.
QC	Male	Suppr.	43	74	105	112	Suppr.
NB	Female	0	3	4	3	4	0
NB	Male	1	7	4	6	6	2
	Female	Suppr.	1	1	3	8	Suppr.
NS	Male	Suppr.	6	8	9	4	Suppr.
5.5	Female	0	Suppr.	Suppr.	0	0	Suppr.
PE	Male	0	Suppr.	Suppr.	0	0	Suppr.
A.I.	Female	0	Suppr.	Suppr.	115 90 68 354 275 163 27 21 13 30 49 27 6 5 1 8 11 5 167 134 122 515 446 367 25 24 26 74 105 112 4 3 4 4 6 6 1 3 8 8 9 4 Suppr. 0 0 Suppr. Suppr. Suppr. Suppr. <t< td=""><td>Suppr.</td><td>Suppr.</td></t<>	Suppr.	Suppr.
NL	Male	0	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
\/T	Female	0	Suppr.	Suppr.	Suppr.	Suppr.	0
YT	Male	0	Suppr.	Suppr.	Suppr.	Suppr.	0
NIT	Female	0	0	0	Suppr.		Suppr.
NT	Male	0	0	1	Suppr.	0	Suppr.
All I	Female	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
NU	Male	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
0	Female	30	243	359	286	250	75
Canada	Male	46	533	1,046	955	727	310

Not available (n/a)

Suppressed (Suppr.) Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules. Data were not available at the time of this publication.

Includes deaths related to all drug or opioid intoxications including, but not limited to, opioids and stimulants.

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants. 2022 data from Manitoba are based on January to March.

Table 14b. Number of accidental apparent stimulant toxicity deaths by sex and age group, by province or territory, 2018 to 2022

Province or	6			Age	group		
territory	Sex	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
DO	Female	2	39	66	47	47	17
BC	Male	11	131	200	195	220	82
014	Female	1	5	11	9	6	0
SK	Male	0	11	14	12	4	4
140	Female	n/a	n/a	n/a	n/a	n/a	n/a
MB	Male	n/a	n/a	n/a	n/a	n/a	n/a
	Female	4	53	71	48	46	11
ON	Male	8	100	184	163	150	47
0.0	Female	0	9	5	10	6	1
QC	Male	3	16	16	21	37	20
NO	Female	Suppr.	2	2	1	0	Suppr.
NS	Male	Suppr.	6	3	2	5	Suppr.
	Female	n/a	n/a	n/a	n/a	n/a	n/a
NL	Male	n/a	n/a	n/a	n/a	n/a	n/a
	Female	n/a	n/a	n/a	n/a	n/a	n/a
YT	Male	n/a	n/a	n/a	n/a	n/a	n/a
NE	Female	n/a	n/a	n/a	n/a	n/a	n/a
NT	Male	n/a	n/a	n/a	n/a	n/a	n/a

Province or	Cov			Age	group		
territory	Sex	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
DO	Female	5	20	33	27	27	10
BC	Male	3	59	94	84	76	42
OV	Female	0	10	13	5	4	1
SK	Male	1	10	21	13	11	4
MD	Female	0	7	7	2	2	0
MB	Male	1	11	16	19	7	1
ON	Female	3	47	81	55	58	9
	Male	10	125	200	158	163	81
00	Female	0	7	10	6	8	2
QC	Male	4	13	15	20	30	19
NS	Female	Suppr.	0	3	1	0	Suppr.
INO	Male	Suppr.	4	4	4	5	Suppr.
NII	Female	n/a	n/a	n/a	n/a	n/a	n/a
NL	Male	n/a	n/a	n/a	n/a	n/a	n/a
VT	Female	n/a	n/a	n/a	n/a	n/a	n/a
YT	Male	n/a	n/a	n/a	n/a	n/a	n/a
NT	Female	n/a	n/a	n/a	n/a	n/a	n/a
INI	Male	n/a	n/a	n/a	n/a	n/a	n/a

Province or	0			Age (group		
territory	Sex	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
BC	Female	4	35	45	44	42	22
ВС	Male	10	109	177	200	206	89
SK	Female	2	16	17	11	12	2
SK	Male	2	17	44	27	22	9
MD	Female	3	24	26	27	6	3
MB	Male	3	27	52	37	24	8
ON	Female	7	64	135	95	75	22
ON	Male	16	208	350	301	305	110
00	Female	0	7	10	9	14	2
QC	Male	3	8	22	36	51	23
NC	Female	Suppr.	2	1	1	0	Suppr.
NS	Male	Suppr.	5	5	6	7	Suppr.
NII.	Female	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	0
NL	Male	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	0
\/T	Female	n/a	n/a	n/a	n/a	n/a	n/a
YT	Male	n/a	n/a	n/a	n/a	n/a	n/a
NT	Female	0	0	0	0	0	0
NT	Male	0	1	2	0	0	0

Province or	Sex		Age group							
territory	Sex	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more			
ВС	Female	5	35	41	34	48	7			
BC	Male	4	60	123	130	144	80			
SK	Female	3	30	26	15	10	2			
SK	Male	1	32	49	45	37	9			
MD	Female	4	22	35	16	9	7			
MB	Male	2	29	62	45	32	12			
ON	Female	7	106	170	113	86	25			
ON	Male	13	229	418	378	325	155			
00	Female	n/a	n/a	n/a	n/a	n/a	n/a			
QC	Male	n/a	n/a	n/a	n/a	n/a	n/a			
NC	Female	Suppr.	5	2	0	2	Suppr.			
NS	Male	Suppr.	6	7	3	4	Suppr.			
A.II	Female	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.			
NL	Male	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.			
VT	Female	0	Suppr.	Suppr.	Suppr.	0	Suppr.			
YT	Male	0	Suppr.	Suppr.	Suppr.	0	Suppr.			
NIT	Female	0	0	0	Suppr.	0	Suppr.			
NT	Male	0	0	1	Suppr.	0	Suppr.			

Province or	Sex			Age	group		
territory	367	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
ВС	Female	0	7	11	3	7	2
ьс	Male	0	16	41	49	35	15
SK	Female	1	14	20	17	7	2
SN	Male	2	18	26	40	19	11
MD	Female	0	5	6	5	1	1
MB -	Male	2	5	9	9	5	2
ON	Female	4	76	121	111	81	27
ON	Male	10	169	350	334	312	156
QC	Female	n/a	n/a	n/a	n/a	n/a	n/a
QC	Male	n/a	n/a	n/a	n/a	n/a	n/a
NS	Female	Suppr.	2	1	3	2	Suppr.
INS	Male	Suppr.	6	7	8	6	Suppr.
NL	Female	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
INL	Male	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
VT	Female	0	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
YT	Male	0	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
NIT	Female	0	0	0	Suppr.	0	Suppr.
NT	Male	0	0	1	Suppr.	0	Suppr.

Suppressed (Suppr.) Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules.

Not available (n/a) Data were not available at the time of this publication.

Note(s):

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants. 2022 data from Manitoba are based on January to March.

Table 15a. Percentage of accidental apparent opioid toxicity deaths by type of opioids and sex, by province or territory, 2018 to 2022

Partiary Main Female Female Main Main	Province or		20	2018	20	2019	20	2020	20	2021	20	2022
Fentlanyl analogues 89% 20% 76% 24% 83% 17% 21% 21% 28% 83% Fentlanyl analogues 88% 11% 81% 13% 77% 25% 77% 25% 83% 83% Non-fentlanyl opioids 77% 22% 66% 32% 77% 25% 77% 25% 73%	territory	i ype oi opioids	Male	Female								
Fentanyl analogues 89% 11% 81% 19% 79% 27% 25% 83% 83% 77% 25% 77% 25% 77% 25% 77% 25% 77% 25% 77% 25% 77% 25% 77% 25% 77% 25% 77% 25% 77% 25% 77% 25% 75% 27% 26% 77% 25% 77% 27% 27% 26% 77% 27%		Fentanyl	%08	20%	%92	24%	83%	17%	%62	21%	83%	17%
Non-fentanyl opioids 77% 23% 68% 32% 75% 75% 25% 77% 23% 76% 25% 77% 23% 77% 23% 77% 23% 77% 23% 77% 22% 77% 23% 78% 22% 77% 23% 78% 22% 77% 23% 78% 22% 77% 23% 78% 22% 77% 78% 22% 77% 78% 22% 78% 78% 22% 78% 78% 22% 78% 78% 22% 78% 78% 22% 78% 78% 22% 78% 25% 78% 78% 25% 78% 78% 68% 78% 68% 78% 68% 78% 68% 78% 68% 78% 68% 78% 68% 78% 68% 78% 78% 68% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78% 78%	BC	Fentanyl analogues	%68	11%	81%	19%	%62	21%	75%	25%	83%	17%
Fentanyl 78% 22% 77% 23% 78% 78% 23% 78% 28% 78% 78% 28% 78% 28% 78% 78% 28% 78% 28% 78% 78% 28% 78		Non-fentanyl opioids	77%	23%	%89	32%	75%	25%	71%	29%	73%	27%
Fentlanyl analogues 78% 25% 75% 25% 79% 79% 78% 26% 74% Non-fentanyl analogues 61% 39% 65% 35% 67% 33% 68% 32% 66% Fentanyl analogues Suppr. Suppr. 67% 33% 75% 68% 32% 66% Fentanyl analogues Suppr. Suppr. 67% 33% 75% 68% 32% 66% Non-fentanyl analogues Suppr. 178 88% 17% 64% 66% 33% 66% 36% 66%		Fentanyl	78%	22%	77%	23%	78%	22%	74%	26%	73%	27%
Non-fentanyl opioids 61% 39% 65% 36% 67% 33% 66% 32% 66% 32% 67% 33% 67% 67% 32% 67% 32% 67% 32% 67% 32% 67% 32% 67% 32% 66% 32% 66% 92% 66% 32% 66% 92% 66% 32% 66% 92% 66% 92% 66% 92% 66% 92% 66% 92% 66% 92% 66% 92% 96%	AB	Fentanyl analogues	78%	22%	75%	25%	%62	21%	%82	22%	74%	26%
Fentlanyl 68% 32% 70% 30% 73% 67% 38% 68% 32% 66% Fentlanyl analogues Suppr. Suppr. 67% 33% 75% 68% 32% 66% Non-fentlanyl analogues 54% 46% 62% 38% 59% 41% 60% 40% 54% Fentlanyl analogues n/a n/a 13% 64% 36% 46% 65% 54% 66% 54% 66% 54% 66% 54% 66% 54% 66% 54% 66% 54% 66% 54% 66% 54% 66% 54% 66% 54% 66% 54% 66% 54% 66% 54% 66% 55% 66% 55%		Non-fentanyl opioids	61%	39%	65%	35%	%29	33%	%89	32%	65%	35%
Fentanyl analogues Suppr. GPW 33% 75% 25% 68% 32% 66% Non-fentanyl opicids 54% 46% 62% 38% 59% 41% 60% 40% 54% Fentanyl n/a n/a 88% 13% 64% 36% 66% 34% 65% Fentanyl analogues n/a n/a n/a 88% 17% 54% 46% 65% 35% 64% Non-fentanyl opicids n/a n/a 77% 25% 78% 52% 77% 58% 59% 41% 65% Non-fentanyl opicids n/a n/a 77% 25% 78% 50% 75% 25% 77% 75% 78% 78% 50% 77% 75% 75% 78% 78% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75% 75%		Fentanyl	%89	32%	%02	30%	73%	27%	%89	32%	%59	35%
Non-fentanyl opioids 54% 46% 62% 38% 59% 41% 60% 40% 54% Fentanyl n/a n/a n/a 88% 13% 64% 66% 34% 65% Fentanyl analogues n/a n/a n/a 17% 54% 46% 65% 34% 65% Non-fentanyl opioids n/a n/a 75% 25% 78% 54% 46% 65% 34% 65% Fentanyl analogues n/a n/a 77% 25% 78% 22% 75% 25% 77% 78% 25% 77% 78% 25% 77% 78% 25% 77% 75%	SK	Fentanyl analogues	Suppr.	Suppr.	%29	33%	75%	25%	%89	32%	%99	34%
Fentlanyl n/a n/a 88% 13% 64% 36% 66% 34% 65% Fentlanyl analogues n/a n/a n/a 13% 17% 54% 66% 65% 35% 64% Non-fentlanyl opioids n/a n/a 52% 48% 54% 46% 65% 41% 59% 64% Non-fentlanyl opioids n/a n/a 75% 25% 78% 52% 77% 55% 77% 55% 77% 55% 77% 55% 77% 55% 77% 77% 77% 77% 78% 67% 78% 77% <		Non-fentanyl opioids	54%	46%	62%	38%	%69	41%	%09	40%	54%	46%
Fentanyl analogues n/a n/a 83% 17% 54% 46% 65% 35% 64% Non-fentanyl opioids n/a n/a 52% 48% 54% 46% 59% 41% 59% Fentanyl opioids n/a n/a 75% 25% 78% 52% 75% 25% 77% Fentanyl analogues 76% 24% 77% 23% 67% 33% 69% 31% 69% 77% Fentanyl analogues 76% 24% 77% 25% 77% 20% 77% 59% 87% 69% 77% 77% Fentanyl analogues Suppr. Suppr. Suppr. Suppr. 88% 13% 66% 74% 88% 74% 80% 74% 80% 74% 80% 74% 80% 74% 80% 74% 80% 74% 80% 74% 80% 74% 80% 74% 80% 80% 80% 80% <td< td=""><td></td><td>Fentanyl</td><td>n/a</td><td>n/a</td><td>88%</td><td>13%</td><td>64%</td><td>36%</td><td>%99</td><td>34%</td><td>%59</td><td>35%</td></td<>		Fentanyl	n/a	n/a	88%	13%	64%	36%	%99	34%	%59	35%
Non-fentanyl opioids n/a n/a 52% 48% 54% 46% 59% 41% 59% Fentanyl analogues 75% 25% 75% 25% 78% 52% 75% 77% Fentanyl analogues 76% 24% 77% 23% 80% 20% 73% 27% 75% Non-fentanyl opioids 66% 31% 63% 37% 66% 34% 68% 32% 74% 50% 75% Non-fentanyl opioids 63% 37% 66% 34% 68% 32% 74% 26% 74% Fentanyl analogues 80% 34% 68% 32% 74% 26% 74% Fentanyl analogues 1/a	MB	Fentanyl analogues	n/a	n/a	83%	17%	54%	46%	%59	35%	64%	36%
Fentanyl analogues 75% 25% 75% 25% 78% 22% 78% 25% 77% 77% 23% 78% 25% 77% 77% 77% 77% 23% 60% 73% 27% 77% 77% 78% 78% 27% 78% 77% 78%		Non-fentanyl opioids	n/a	n/a	97%	48%	54%	46%	%69	41%	26%	41%
Fentanyl analogues 76% 24% 77% 23% 80% 20% 73% 27% 75% Non-fentanyl opioids 69% 31% 63% 37% 67% 33% 69% 31% 69% Fentanyl opioids 69% 31% 65% 78% 22% 71% 29% 87% 13% 69% Non-fentanyl analogues Suppr. Suppr. Suppr. Suppr. Suppr. 34% 68% 32% 74% 50% 74% Fentanyl analogues n/a n/a n/a n/a n/a 1/a 52% 48% 57% 40% 88% Non-fentanyl analogues 75% 25% 80% 20% 80% 50% 80% 52% 66% 80% 52% 66% 60% 40% 80% 80% 52% 40% 80% 80% 80% 80% 80% 80% 80% 80% 80% 80% 80% 80% 80%		Fentanyl	75%	25%	75%	25%	78%	22%	75%	25%	%//	23%
Non-fentanyl opioids 69% 31% 63% 37% 67% 63% 93% 69% 31% 69% Fentanyl analogues 74% 26% 78% 22% 71% 29% 87% 13% 85% Fentanyl analogues Suppr. Suppr. Suppr. Suppr. Suppr. 88% 13% 80% 74% 80% Fentanyl analogues n/a n/a n/a n/a n/a n/a n/a 80% 52% 60% 40% 80% Non-fentanyl opioids 43% 57% 46% 54% 52% 48% 52% 80% 52% 80% Fentanyl analogues 75% 25% 75% 25% 80% 20% 80pr.	NO	Fentanyl analogues	%92	24%	77%	23%	%08	20%	73%	27%	75%	25%
Fentanyl analogues Suppr.		Non-fentanyl opioids	%69	31%	63%	37%	%29	33%	%69	31%	%69	31%
Fentanyl analogues Suppr.		Fentanyl	74%	26%	78%	22%	71%	78%	87%	13%	85%	15%
Non-fentanyl opioids 63% 37% 66% 34% 68% 32% 74% 26% 74% 75% 60% 74% 75% 60% 74% 75%	ОС	Fentanyl analogues	Suppr.	Suppr.	Suppr.	Suppr.	%88	13%	Suppr.	Suppr.	Suppr.	Suppr.
Fentanyl analogues n/a n/a n/a n/a n/a n/a n/a n/a n/a 60% 40% 80% 80% Fentanyl analogues n/a n/a n/a n/a n/a 67% 60% 88% 88% Non-fentanyl opioids 43% 57% 46% 54% 52% 48% 57% 43% 52% Fentanyl analogues 75% 25% Suppr. Suppr. Suppr. Suppr. 83% Non-fentanyl opioids 68% 32% 70% 30% 67% 55% 67%		Non-fentanyl opioids	%89	37%	%99	34%	%89	32%	74%	79%	74%	76%
Fentanyl analogues n/a n/a n/a n/a n/a 65% 65% 88% 88% 88% 88% 88% 88% 88% 88% 88% 88% 88% 88% 88% 88% 88% 88% 88% 88% 88% 85% 80% 20% 80% 20% 80pr. 83% 83% Fentanyl analogues 75% 25% 8upr. 8upr. 8uppr. 8uppr. 8uppr. 8uppr. 67% 70% Non-fentanyl opioids 68% 32% 70% 30% 67% 65% 87% 67%		Fentanyl	Suppr.	Suppr.	%08	20%	75%	25%	%09	40%	%08	20%
Non-fentanyl opioids 43% 57% 46% 54% 52% 48% 57% 43% 52% Fentanyl analogues 75% 25% 75% 25% 80% 20% Suppr. 83% Non-fentanyl opioids 68% 32% 70% 30% 67% 33% 65% 85% 67%	NB	Fentanyl analogues	n/a	n/a	n/a	n/a	n/a	n/a	%09	%09	88%	13%
Fentanyl Analogues 75% 25% 75% 25% 80% 20% Suppr. Suppr. 83% Non-fentanyl opioids 68% 32% 70% 30% 67% 33% 65% 35% 67%		Non-fentanyl opioids	43%	21%	46%	54%	52%	48%	21%	43%	52%	48%
Fentanyl analogues 75% 25% Suppr. Suppr. Suppr. Suppr. Suppr. Suppr. 67% 33% 65% 35% 67%		Fentanyl	75%	25%	75%	25%	%08	20%	Suppr.	Suppr.	83%	17%
68% 32% 70% 30% 67% 33% 65% 35% 67%	NS	Fentanyl analogues	75%	25%	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	%29	33%
		Non-fentanyl opioids	%89	32%	%02	30%	%29	33%	%59	35%	%29	33%

Province or	Type of oniting	20	2018	20	2019	20	2020	20	2021	2022	22
territory	spioido lo adá.	Male	Female								
	Fentanyl	n/a	n/a	n/a	n/a	Suppr.	Suppr.	%0	%0	%0	%0
PE	Fentanyl analogues	n/a	n/a	n/a	n/a	%0	%0	%0	%0	%0	%0
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Fentanyl	n/a	n/a	n/a	n/a	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
N	Fentanyl analogues	n/a	n/a	n/a	n/a	Suppr.	Suppr.	%0	%0	%0	%0
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	Suppr.	Suppr.	%69	41%	%99	44%
	Fentanyl	n/a	n/a	n/a	n/a	Suppr.	Suppr.	61%	39%	44%	26%
YT	Fentanyl analogues	n/a	n/a	n/a	n/a	%0	%0	Suppr.	Suppr.	%0	%0
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Fentanyl	n/a	n/a	n/a	n/a	Suppr.	Suppr.	Suppr.	Suppr.	%29	33%
L	Fentanyl analogues	n/a	n/a	n/a	n/a	%0	%0	%0	%0	%29	33%
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	%0	%0	%29	33%	%0	%0
	Fentanyl	Suppr.									
NO	Fentanyl analogues	Suppr.									
	Non-fentanyl opioids	Suppr.									
	Fentanyl	78%	22%	%92	24%	78%	22%	75%	72%	%92	24%
Canada	Fentanyl analogues	%08	%07	78%	22%	78%	22%	73%	27%	73%	27%
	Non-fentanyl opioids	%69	31%	64%	36%	%29	33%	%89	32%	%89	32%

Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules. Suppressed (Suppr.)

Not available (n/a) Data were not available at the time of this publication.

includes deaths related to all drug or opioid intoxications including, but not limited to, opioids and stimulants.

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

2022 data from Manitoba are based on January to March.

Table 15b. Percentage of accidental apparent stimulant toxicity deaths by type of stimulants and sex, by province or territory, 2018 to 2022

Province or	i i di	20	2018	20	2019	20	2020	20	2021	20	2022
territory	iype oi sumulamis	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
	Cocaine	%62	21%	73%	27%	81%	19%	%//	23%	%98	14%
BC	Methamphetamine	77%	23%	75%	25%	%62	21%	75%	25%	83%	17%
	Other stimulants	88%	13%	73%	27%	74%	26%	%89	32%	%29	33%
	Cocaine	%29	33%	83%	17%	%29	33%	61%	39%	73%	28%
SK	Methamphetamine	97%	48%	28%	42%	%/9	33%	%69	31%	64%	36%
	Other stimulants	45%	%99	%89	38%	%29	33%	%02	30%	Suppr.	Suppr.
	Cocaine	n/a	n/a	75%	25%	%29	38%	%89	33%	%29	33%
MB	Methamphetamine	n/a	n/a	81%	19%	%19	%68	%69	31%	%59	35%
	Other stimulants	n/a	n/a	Suppr.	Suppr.	%29	38%	%29	33%	64%	36%
	Cocaine	73%	27%	75%	25%	%9/	24%	74%	26%	75%	25%
NO	Methamphetamine	72%	28%	71%	78%	%9/	25%	%9/	24%	76%	24%
	Other stimulants	77%	23%	62%	38%	%89	32%	%99	34%	%89	32%
	Cocaine	81%	19%	%9/	24%	%//	23%	n/a	n/a	n/a	n/a
ОС	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
	Other stimulants	75%	25%	75%	25%	78%	23%	n/a	n/a	n/a	n/a
	Cocaine	71%	78%	86%	11%	81%	19%	%02	30%	82%	18%
SN	Methamphetamine	%29	33%	89%	11%	%0	%0	%29	33%	67%	33%
	Other stimulants	Suppr.	Suppr.	75%	25%	71%	29%	Suppr.	Suppr.	71%	29%

Province or	i i	20	2018	20	2019	20	2020	20	2021	2022	22
territory	Type of sumulants	Male	Female	Male	Female	Male	Female	Male	Female	Male	Female
	Cocaine	n/a	n/a	n/a	n/a	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
N	Methamphetamine	n/a	n/a	n/a	n/a	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Other stimulants	n/a	n/a	n/a	n/a	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Cocaine	n/a	n/a	n/a	n/a	n/a	n/a	Suppr.	Suppr.	Suppr.	Suppr.
ΥT	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a	%0	%0	%0	%0
	Other stimulants	n/a	n/a	n/a	n/a	n/a	n/a	%0	%0	Suppr.	Suppr.
	Cocaine	n/a	n/a	n/a	n/a	Suppr.	Suppr	Suppr.	Suppr.	%29	33%
TN	Methamphetamine	n/a	n/a	n/a	n/a	%0	%0	%0	%0	%0	%0
	Other stimulants	n/a	n/a	n/a	n/a	%0	%0	Suppr.	Suppr.	%0	%0
	Cocaine	%92	24%	75%	25%	%92	24%	74%	26%	%92	24%
Canada	Methamphetamine	74%	79%	72%	28%	74%	%97	74%	%97	75%	25%
	Other stimulants	%92	24%	%69	31%	%89	32%	%29	33%	%29	33%

Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules. Suppressed (Suppr.) Not available (n/a)

Data were not available at the time of this publication.

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved. Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants.

2022 data from Manitoba are based on January to March.

Table 16a. Percentage of accidental apparent opioid toxicity deaths by type of opioids and age group, by province or territory, 2018 to 2022

Province or	_ , , , , ,			Age	group		
territory	Type of opioids	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
	Fentanyl	2%	20%	27%	22%	22%	8%
ВС	Fentanyl analogues	7%	21%	26%	19%	19%	7%
	Non-fentanyl opioids	1%	16%	24%	21%	26%	11%
	Fentanyl	2%	27%	33%	20%	14%	4%
AB	Fentanyl analogues	3%	27%	32%	19%	15%	4%
	Non-fentanyl opioids	1%	15%	22%	21%	29%	12%
	Fentanyl	0%	30%	36%	19%	13%	2%
SK	Fentanyl analogues	0%	40%	60%	0%	0%	0%
	Non-fentanyl opioids	0%	19%	18%	21%	26%	17%
	Fentanyl	n/a	n/a	n/a	n/a	n/a	n/a
MB	Fentanyl analogues	n/a	n/a	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	n/a	n/a
	Fentanyl	1%	22%	32%	22%	19%	4%
ON	Fentanyl analogues	2%	27%	35%	22%	14%	1%
	Non-fentanyl opioids	2%	16%	25%	22%	23%	12%
	Fentanyl	0%	11%	33%	19%	22%	15%
QC	Fentanyl analogues	0%	22%	22%	11%	44%	0%
	Non-fentanyl opioids	1%	14%	27%	23%	23%	13%
	Fentanyl	0%	0%	0%	Suppr.	0%	Suppr.
NB	Fentanyl analogues	n/a	n/a	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	0%	9%	22%	22%	35%	13%
	Fentanyl	13%	25%	25%	25%	13%	0%
NS	Fentanyl analogues	0%	75%	0%	25%	0%	0%
	Non-fentanyl opioids	0%	21%	26%	21%	19%	13%

Province or	Town of outstan			Age	group		
territory	Type of opioids	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
	Fentanyl	n/a	n/a	n/a	n/a	n/a	n/a
PE	Fentanyl analogues	n/a	n/a	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	n/a	n/a
	Fentanyl	n/a	n/a	n/a	n/a	n/a	n/a
NL	Fentanyl analogues	n/a	n/a	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	n/a	n/a
	Fentanyl	n/a	n/a	n/a	n/a	n/a	n/a
YT	Fentanyl analogues	n/a	n/a	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	n/a	n/a
	Fentanyl	n/a	n/a	n/a	n/a	n/a	n/a
NT	Fentanyl analogues	n/a	n/a	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	n/a	n/a
	Fentanyl	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
NU	Fentanyl analogues	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Non-fentanyl opioids	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Fentanyl	2%	22%	30%	21%	19%	6%
Canada	Fentanyl analogues	3%	26%	31%	20%	16%	4%
	Non-fentanyl opioids	1%	16%	24%	22%	25%	12%

Province or	-			Age	group		
territory	Type of opioids	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
	Fentanyl	2%	18%	31%	21%	19%	8%
BC	Fentanyl analogues	3%	17%	26%	21%	20%	13%
	Non-fentanyl opioids	2%	16%	23%	22%	24%	14%
	Fentanyl	2%	25%	34%	19%	15%	3%
AB	Fentanyl analogues	6%	22%	25%	23%	17%	6%
	Non-fentanyl opioids	2%	15%	24%	23%	26%	10%
	Fentanyl	3%	25%	43%	15%	13%	3%
SK	Fentanyl analogues	0%	33%	42%	8%	17%	0%
	Non-fentanyl opioids	0%	17%	13%	27%	35%	8%
	Fentanyl	0%	44%	38%	19%	0%	0%
МВ	Fentanyl analogues	0%	67%	0%	33%	0%	0%
	Non-fentanyl opioids	3%	14%	24%	17%	34%	7%
	Fentanyl	1%	25%	32%	20%	17%	5%
ON	Fentanyl analogues	1%	21%	31%	20%	21%	7%
	Non-fentanyl opioids	2%	15%	23%	19%	30%	12%
	Fentanyl	7%	22%	22%	26%	19%	4%
QC	Fentanyl analogues	0%	0%	0%	0%	Suppr.	Suppr.
	Non-fentanyl opioids	1%	11%	17%	27%	25%	19%
	Fentanyl	0%	0%	60%	40%	0%	0%
NB	Fentanyl analogues	n/a	n/a	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	0%	8%	25%	17%	25%	25%
	Fentanyl	0%	50%	0%	25%	25%	0%
NS	Fentanyl analogues	0%	0%	0%	0%	Suppr.	Suppr.
	Non-fentanyl opioids	2%	14%	23%	26%	19%	16%

Province or				Age (group		
territory	Type of opioids	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
	Fentanyl	n/a	n/a	n/a	n/a	n/a	n/a
PE	Fentanyl analogues	n/a	n/a	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	n/a	n/a
	Fentanyl	n/a	n/a	n/a	n/a	n/a	n/a
NL	Fentanyl analogues	n/a	n/a	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	n/a	n/a
	Fentanyl	n/a	n/a	n/a	n/a	n/a	n/a
YT	Fentanyl analogues	n/a	n/a	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	n/a	n/a
	Fentanyl	n/a	n/a	n/a	n/a	n/a	n/a
NT	Fentanyl analogues	n/a	n/a	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	n/a	n/a
	Fentanyl	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
NU	Fentanyl analogues	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Non-fentanyl opioids	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Fentanyl	2%	23%	33%	20%	17%	5%
Canada	Fentanyl analogues	2%	21%	30%	20%	20%	7%
	Non-fentanyl opioids	2%	14%	22%	22%	28%	13%

Province or	war a santata			Age	group		
territory	Type of opioids	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
	Fentanyl	2%	17%	25%	24%	23%	9%
BC	Fentanyl analogues	2%	16%	25%	23%	23%	10%
	Non-fentanyl opioids	1%	13%	19%	20%	29%	18%
	Fentanyl	2%	20%	30%	24%	18%	6%
AB	Fentanyl analogues	1%	13%	28%	29%	24%	4%
	Non-fentanyl opioids	2%	14%	23%	23%	25%	13%
	Fentanyl	2%	25%	34%	21%	14%	3%
SK	Fentanyl analogues	3%	22%	37%	20%	14%	3%
	Non-fentanyl opioids	2%	16%	21%	20%	27%	13%
	Fentanyl	2%	21%	37%	28%	9%	4%
MB	Fentanyl analogues	0%	8%	50%	25%	17%	0%
	Non-fentanyl opioids	2%	18%	26%	27%	17%	10%
	Fentanyl	1%	19%	31%	23%	20%	6%
ON	Fentanyl analogues	0%	15%	29%	20%	24%	12%
	Non-fentanyl opioids	1%	14%	25%	22%	25%	13%
	Fentanyl	3%	16%	28%	25%	16%	12%
QC	Fentanyl analogues	0%	13%	13%	63%	13%	0%
	Non-fentanyl opioids	3%	16%	24%	16%	21%	19%
	Fentanyl	0%	25%	25%	50%	0%	0%
NB	Fentanyl analogues	n/a	n/a	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	0%	9%	15%	27%	27%	21%
	Fentanyl	0%	30%	40%	0%	10%	20%
NS	Fentanyl analogues	0%	33%	33%	0%	33%	0%
	Non-fentanyl opioids	0%	22%	17%	42%	14%	6%

Province or				Age (group		
territory	Type of opioids	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
	Fentanyl	0%	Suppr.	0%	Suppr.	0%	0%
PE	Fentanyl analogues	0%	0%	0%	0%	0%	0%
	Non-fentanyl opioids	0%	Suppr.	0%	Suppr.	0%	Suppr.
	Fentanyl	0%	Suppr.	Suppr.	Suppr.	0%	0%
NL	Fentanyl analogues	0%	0%	Suppr.	0%	0%	Suppr.
	Non-fentanyl opioids	Suppr.	Suppr.	43%	Suppr.	36%	0%
	Fentanyl	0%	Suppr.	Suppr.	Suppr.	Suppr.	0%
YT	Fentanyl analogues	0%	0%	0%	0%	0%	0%
	Non-fentanyl opioids	0%	0%	Suppr.	Suppr.	0%	0%
	Fentanyl	0%	33%	67%	0%	0%	0%
NT	Fentanyl analogues	0%	0%	0%	0%	0%	0%
-	Non-fentanyl opioids	0%	0%	0%	0%	0%	0%
	Fentanyl	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
NU	Fentanyl analogues	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Non-fentanyl opioids	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Fentanyl	2%	19%	29%	24%	19%	7%
Canada	Fentanyl analogues	2%	17%	29%	24%	22%	8%
	Non-fentanyl opioids	1%	15%	23%	22%	25%	14%

Province or	*			Age	group		
territory	Type of opioids	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
	Fentanyl	1%	15%	25%	21%	26%	12%
BC	Fentanyl analogues	2%	14%	23%	21%	29%	11%
	Non-fentanyl opioids	1%	13%	19%	21%	32%	14%
	Fentanyl	2%	20%	33%	23%	17%	6%
AB	Fentanyl analogues	1%	16%	31%	25%	20%	7%
	Non-fentanyl opioids	2%	17%	25%	23%	20%	14%
	Fentanyl	1%	25%	24%	26%	17%	6%
SK	Fentanyl analogues	0%	26%	27%	26%	16%	5%
	Non-fentanyl opioids	1%	8%	19%	29%	27%	15%
	Fentanyl	1%	21%	41%	20%	12%	4%
MB	Fentanyl analogues	2%	23%	41%	17%	12%	5%
	Non-fentanyl opioids	2%	19%	27%	25%	18%	8%
	Fentanyl	1%	19%	30%	23%	19%	7%
ON	Fentanyl analogues	5%	16%	27%	28%	19%	6%
	Non-fentanyl opioids	1%	10%	23%	23%	27%	16%
	Fentanyl	Suppr.	14%	34%	22%	18%	Suppr.
QC	Fentanyl analogues	Suppr.	Suppr.	47%	Suppr.	Suppr.	Suppr.
	Non-fentanyl opioids	3%	10%	26%	27%	19%	14%
	Fentanyl	0%	40%	20%	20%	20%	0%
NB	Fentanyl analogues	0%	50%	0%	0%	50%	0%
	Non-fentanyl opioids	0%	14%	20%	37%	14%	14%
	Fentanyl	0%	67%	17%	0%	17%	0%
NS	Fentanyl analogues	0%	33%	33%	0%	33%	0%
	Non-fentanyl opioids	0%	19%	23%	23%	19%	15%

Province or	Town of outstan			Age (group		
territory	Type of opioids	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
	Fentanyl	0%	0%	0%	0%	0%	0%
PE	Fentanyl analogues	0%	0%	0%	0%	0%	0%
	Non-fentanyl opioids	0%	0%	50%	Suppr.	Suppr.	0%
	Fentanyl	0%	Suppr.	Suppr.	0%	Suppr.	Suppr.
NL	Fentanyl analogues	0%	0%	0%	0%	0%	0%
	Non-fentanyl opioids	0%	Suppr.	35%	35%	Suppr.	Suppr.
	Fentanyl	0%	Suppr.	35%	35%	Suppr.	Suppr.
YT	Fentanyl analogues	0%	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Non-fentanyl opioids	0%	0%	0%	Suppr.	0%	Suppr.
	Fentanyl	0%	0%	50%	50%	0%	0%
NT	Fentanyl analogues	0%	0%	0%	0%	0%	0%
	Non-fentanyl opioids	0%	0%	67%	33%	0%	0%
	Fentanyl	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
NU	Fentanyl analogues	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Non-fentanyl opioids	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Fentanyl	1%	19%	30%	23%	19%	7%
Canada	Fentanyl analogues	2%	18%	30%	23%	20%	7%
	Non-fentanyl opioids	1%	12%	24%	24%	24%	14%

Province or				Age	group		
territory	Type of opioids	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
	Fentanyl	1%	13%	29%	26%	23%	8%
BC	Fentanyl analogues	0%	9%	28%	28%	26%	9%
	Non-fentanyl opioids	2%	15%	19%	21%	25%	19%
	Fentanyl	3%	18%	32%	25%	15%	7%
AB	Fentanyl analogues	3%	16%	30%	25%	20%	6%
	Non-fentanyl opioids	2%	11%	25%	26%	24%	12%
	Fentanyl	2%	18%	28%	33%	16%	2%
SK	Fentanyl analogues	3%	18%	28%	32%	17%	3%
	Non-fentanyl opioids	1%	13%	16%	28%	27%	13%
	Fentanyl	4%	24%	30%	28%	9%	4%
MB	Fentanyl analogues	2%	24%	31%	29%	9%	4%
	Non-fentanyl opioids	3%	16%	25%	38%	13%	6%
	Fentanyl	1%	16%	31%	25%	19%	7%
ON	Fentanyl analogues	1%	13%	28%	26%	23%	9%
	Non-fentanyl opioids	1%	11%	23%	25%	25% 15% 20% 24% 16% 17% 27% 9% 9% 13% 19% 23% 25% 11% Suppr. 24% 27% 13% 29% 33% 0%	15%
	Fentanyl	Suppr.	19%	26%	27%	11%	Suppr.
QC	Fentanyl analogues	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Non-fentanyl opioids	Suppr.	14%	17%	23%	24%	Suppr.
	Fentanyl	0%	13%	33%	20%	27%	7%
NB	Fentanyl analogues	0%	25%	25%	25%	13%	13%
-	Non-fentanyl opioids	5%	29%	5%	29%	29%	5%
	Fentanyl	0%	17%	17%	17%	33%	17%
NS	Fentanyl analogues	0%	0%	0%	Suppr.	0%	Suppr.
	Non-fentanyl opioids	2%	13%	18%	24%	24%	18%

Province or	Town of outstan			Age	group		
territory	Type of opioids	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
	Fentanyl	0%	0%	0%	0%	0%	0%
PE	Fentanyl analogues	0%	0%	0%	0%	0%	0%
	Non-fentanyl opioids	0%	Suppr.	Suppr.	0%	0%	Suppr.
	Fentanyl	0%	Suppr.	0%	Suppr.	0%	0%
NL	Fentanyl analogues	0%	0%	0%	0%	0%	0%
	Non-fentanyl opioids	0%	Suppr.	31%	Suppr.	Suppr.	Suppr.
	Fentanyl	0%	28%	50%	Suppr.	Suppr.	0%
YT	Fentanyl analogues	0%	0%	0%	0%	0%	0%
	Non-fentanyl opioids	0%	Suppr.	0%	0%	0%	Suppr.
	Fentanyl	0%	0%	33%	67%	0%	0%
NT	Fentanyl analogues	0%	0%	33%	67%	0%	0%
	Non-fentanyl opioids	0%	0%	0%	0%	0%	0%
	Fentanyl	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
NU	Fentanyl analogues	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Non-fentanyl opioids	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
	Fentanyl	2%	17%	31%	26%	18%	7%
Canada	Fentanyl analogues	2%	16%	29%	27%	20%	7%
	Non-fentanyl opioids	1%	13%	22%	26%	25%	12%

Suppressed (Suppr.)
Not available (n/a)

Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules. Data were not available at the time of this publication.

Includes deaths related to all drug or opioid intoxications including, but not limited to, opioids and stimulants.

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants. 2022 data from Manitoba are based on January to March.

Table 16b. Percentage of accidental apparent stimulant toxicity deaths by type of stimulants and age group, by province or territory, 2018 to 2022

Province or			Age group							
territory	Type of stimulants	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more			
	Cocaine	0%	15%	25%	23%	26%	10%			
ВС	Methamphetamine	1%	17%	27%	24%	23%	8%			
	Other stimulants	13%	38%	28%	3%	19%	0%			
	Cocaine	3%	26%	23%	26%	13%	10%			
SK	Methamphetamine	0%	21%	38%	26%	12%	2%			
	Other stimulants	0%	18%	9%	45%	27%	0%			
	Cocaine	n/a	n/a	n/a	n/a	n/a	n/a			
MB	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a			
	Other stimulants	n/a	n/a	n/a	n/a	n/a	n/a			
	Cocaine	2%	16%	28%	24%	24%	7%			
ON	Methamphetamine	1%	20%	32%	26%	17%	4%			
	Other stimulants	9%	21%	28%	14%	23%	5%			
	Cocaine	1%	18%	15%	18%	34%	15%			
QC	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a			
	Other stimulants	4%	16%	15%	27%	24%	15%			
	Cocaine	5%	33%	19%	14%	24%	5%			
NS	Methamphetamine	33%	33%	33%	0%	0%	0%			
	Other stimulants	0%	50%	50%	0%	0%	0%			

Province or	Type of stimulants			Age (group		
territory	Type of stillidiants	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
	Cocaine	n/a	n/a	n/a	n/a	n/a	n/a
NL	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a
	Other stimulants	n/a	n/a	n/a	n/a	n/a	n/a
	Cocaine	n/a	n/a	n/a	n/a	n/a	n/a
YT	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a
	Other stimulants	n/a	n/a	n/a	n/a	n/a	n/a
	Cocaine	n/a	n/a	n/a	n/a	n/a	n/a
NT	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a
	Other stimulants	n/a	n/a	n/a	n/a	n/a	n/a
Canada	Cocaine	1%	16%	26%	23%	25%	9%
	Methamphetamine	1%	18%	29%	25%	20%	7%
	Other stimulants	7%	23%	22%	19%	22%	7%

Province or			Age group							
territory	Type of stimulants	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more			
	Cocaine	1%	17%	26%	20%	23%	13%			
BC	Methamphetamine	2%	16%	27%	25%	22%	8%			
	Other stimulants	0%	47%	20%	20%	13%	0%			
	Cocaine	0%	13%	48%	22%	13%	4%			
SK	Methamphetamine	1%	24%	36%	18%	15%	6%			
	Other stimulants	0%	13%	50%	13%	25%	0%			
	Cocaine	0%	20%	33%	25%	20%	3%			
MB	Methamphetamine	0%	30%	35%	30%	5%	0%			
	Other stimulants	25%	0%	50%	25%	5%	0%			
	Cocaine	1%	16%	28%	21%	23%	10%			
ON	Methamphetamine	1%	20%	31%	22%	20%	6%			
	Other stimulants	3%	38%	18%	18%	23% 22% 13% 13% 15% 25% 20% 5% 0% 23%	10%			
	Cocaine	1%	16%	18%	20%	29%	16%			
QC	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a			
	Other stimulants	6%	13%	19%	19%	27%	15%			
	Cocaine	0%	17%	22%	22%	22%	17%			
NS	Methamphetamine	0%	33%	22%	11%	11%	22%			
	Other stimulants	25%	0%	25%	50%	0%	0%			

Province or	Time of atimulants			Age (group		
territory	Type of stimulants	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
	Cocaine	n/a	n/a	n/a	n/a	n/a	n/a
NL	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a
	Other stimulants	n/a	n/a	n/a	n/a	n/a	n/a
	Cocaine	n/a	n/a	n/a	n/a	n/a	n/a
YT	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a
	Other stimulants	n/a	n/a	n/a	n/a	n/a	n/a
	Cocaine	n/a	n/a	n/a	n/a	n/a	n/a
NT	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a
	Other stimulants	n/a	n/a	n/a	n/a	n/a	n/a
Canada	Cocaine	1%	16%	27%	21%	23%	11%
	Methamphetamine	1%	20%	30%	23%	19%	6%
	Other stimulants	5%	25%	22%	20%	19%	10%

Province or			Age group							
territory	Type of stimulants	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more			
	Cocaine	1%	15%	21%	25%	27%	12%			
BC	Methamphetamine	2%	15%	25%	25%	23%	11%			
	Other stimulants	7%	48%	15%	15%	13%	2%			
	Cocaine	0%	18%	28%	21%	26%	7%			
SK	Methamphetamine	3%	19%	37%	20%	15%	5%			
	Other stimulants	0%	22%	11%	11%	44%	11%			
	Cocaine	1%	22%	34%	26%	12%	6%			
MB	Methamphetamine	2%	23%	32%	30%	11%	2%			
	Other stimulants	3%	23%	33%	26%	12%	3%			
	Cocaine	1%	15%	26%	24%	24%	9%			
ON	Methamphetamine	2%	17%	33%	23%	21%	4%			
	Other stimulants	9%	20%	28%	22%	27% 23% 13% 26% 15% 44% 12% 11% 24%	4%			
	Cocaine	1%	11%	11%	20%	39%	17%			
QC	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a			
	Other stimulants	3%	4%	25%	30%	30%	9%			
	Cocaine	0%	22%	19%	22%	22%	15%			
NS	Methamphetamine	0%	0%	0%	0%	0%	0%			
	Other stimulants	14%	29%	14%	14%	29%	0%			

Province or	Type of stimulants		Age group							
territory	Type of Stillidiants	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more			
	Cocaine	Suppr.	0%	Suppr.	0%	Suppr.	0%			
NL	Methamphetamine	0%	0%	Suppr.	0%	Suppr.	0%			
	Other stimulants	0%	Suppr.	Suppr.	Suppr.	0%	0%			
	Cocaine	n/a	n/a	n/a	n/a	n/a	n/a			
YT	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a			
	Other stimulants	n/a	n/a	n/a	n/a	n/a	n/a			
	Cocaine	0%	33%	67%	0%	0%	0%			
NT	Methamphetamine	0%	0%	0%	0%	0%	0%			
	Other stimulants	0%	0%	0%	0%	0%	0%			
Canada	Cocaine	1%	16%	25%	24%	25%	10%			
	Methamphetamine	2%	17%	30%	24%	20%	6%			
	Other stimulants	5%	21%	28%	24%	18%	4%			

Province or	Type of stimulants		Age group							
territory	Type of Stillidiants	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more			
	Cocaine	1%	12%	19%	24%	29%	14%			
BC	Methamphetamine	1%	14%	26%	23%	25%	11%			
	Other stimulants	9%	18%	32%	23%	9%	9%			
	Cocaine	0%	26%	28%	15%	24%	7%			
SK	Methamphetamine	1%	24%	29%	25%	17%	4%			
	Other stimulants	10%	10%	30%	40%	10%	0%			
	Cocaine	2%	20%	34%	21%	17%	8%			
MB	Methamphetamine	2%	17%	41%	22%	14%	5%			
	Other stimulants	2%	20%	38%	21%	13%	6%			
	Cocaine	1%	15%	28%	24%	22%	10%			
ON	Methamphetamine	1%	18%	32%	25%	18%	6%			
	Other stimulants	2%	24%	35%	16%	29% 25% 9% 24% 17% 10% 14% 13% 22%	5%			
	Cocaine	n/a	n/a	n/a	n/a	n/a	n/a			
QC	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a			
	Other stimulants	n/a	n/a	n/a	n/a	n/a	n/a			
	Cocaine	0%	37%	27%	10%	17%	10%			
NS	Methamphetamine	0%	22%	33%	0%	33%	11%			
	Other stimulants	0%	0%	Suppr.	0%	0%	Suppr.			

Province or	Towns of attended			Age (group		
territory	Type of stimulants	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
	Cocaine	0%	0%	Suppr.	Suppr.	Suppr.	Suppr.
NL	Methamphetamine	0%	Suppr.	Suppr.	Suppr.	Suppr.	0%
	Other stimulants	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.	0%
	Cocaine	0%	Suppr.	Suppr.	Suppr.	0%	Suppr.
YT	Methamphetamine	0%	0%	0%	0%	0%	0%
	Other stimulants	0%	0%	0%	0%	0%	0%
	Cocaine	0%	0%	50%	50%	0%	0%
NT	Methamphetamine	0%	0%	0%	0%	0%	0%
	Other stimulants	0%	0%	0%	Suppr.	0%	Suppr.
	Cocaine	1%	15%	27%	24%	23%	11%
Canada	Methamphetamine	1%	18%	31%	24%	19%	7%
	Other stimulants	3%	20%	36%	21%	14%	5%

Province or	_ ,,,,,		Age group							
territory	Type of stimulants	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more			
	Cocaine	0%	10%	25%	27%	28%	10%			
BC	Methamphetamine	0%	14%	29%	28%	19%	9%			
	Other stimulants	0%	50%	17%	0%	17%	17%			
	Cocaine	0%	10%	15%	38%	18%	20%			
SK	Methamphetamine	2%	20%	27%	32%	13%	6%			
	Other stimulants	0%	0%	0%	Suppr.	0%	Suppr.			
	Cocaine	6%	19%	33%	22%	14%	6%			
MB	Methamphetamine	3%	29%	29%	26%	9%	3%			
	Other stimulants	5%	19%	33%	31%	10%	2%			
	Cocaine	1%	13%	24%	26%	24%	12%			
ON	Methamphetamine	1%	15%	32%	25%	21%	7%			
	Other stimulants	2%	35%	23%	19%	28% 19% 17% 18% 13% 0% 14% 9% 10% 24%	2%			
	Cocaine	n/a	n/a	n/a	n/a	n/a	n/a			
QC	Methamphetamine	n/a	n/a	n/a	n/a	n/a	n/a			
	Other stimulants	n/a	n/a	n/a	n/a	n/a	n/a			
	Cocaine	0%	21%	18%	24%	16%	21%			
NS	Methamphetamine	0%	17%	33%	17%	33%	0%			
	Other stimulants	0%	0%	29%	43%	14%	14%			

Province or	Tura of atimulanta			Age (group		
territory	Type of stimulants	0 to 19	20 to 29	30 to 39	40 to 49	50 to 59	60 or more
	Cocaine	0%	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
NL	Methamphetamine	0%	Suppr.	0%	0%	Suppr.	0%
	Other stimulants	Suppr.	Suppr.	0%	Suppr.	0%	Suppr.
	Cocaine	0%	Suppr.	Suppr.	Suppr.	Suppr.	Suppr.
YT	Methamphetamine	0%	0%	0%	0%	0%	0%
	Other stimulants	Suppr.	0%	0%	0%	0%	Suppr.
	Cocaine	0%	0%	33%	67%	0%	0%
NT	Methamphetamine	0%	0%	0%	0%	0%	0%
	Other stimulants	0%	0%	0%	0%	0%	0%
	Cocaine	1%	13%	24%	26%	24%	12%
Canada	Methamphetamine	1%	16%	31%	26%	19%	7%
	Other stimulants	3%	27%	28%	24%	14%	4%

Suppressed (Suppr.) Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules.

Not available (n/a) Data were not available at the time of this publication.

Note(s):

Apparent stimulant toxicity death (ASTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is a stimulant, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants. 2022 data from Manitoba are based on January to March.

Table 17. Percentage of accidental apparent opioid toxicity deaths by type of opioids and origin of opioid(s), by province or territory, 2018 to 2022

Bi			Origin		
Province or territory	Type of opioids	Pharmaceutical only	Non-pharmaceutical only	Both	Undetermined
	Fentanyl	0%	100%	0%	0%
ВС	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	0%	0%	0%	100%
	Fentanyl	0%	100%	0%	0%
AB	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	56%	22%	4%	18%
	Fentanyl	13%	87%	0%	0%
SK	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	87%	9%	0% 0% 0% 0% 0% 4% 0%	4%
	Fentanyl	n/a	n/a	0% 0% n/a n/a	n/a
МВ	Fentanyl analogues	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a
	Fentanyl	3%	97%	0%	0%
ON	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	65%	23%	0% 0% 0% 0% 0% 0% 0% 4% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%	6%
	Fentanyl	n/a	n/a	n/a	n/a
QC	Fentanyl analogues	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0	n/a
	Fentanyl	0%	100%	0%	0%
NB	Fentanyl analogues	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	100%	0%	0%	0%

Province or			Origin				
territory	Type of opioids	Pharmaceutical only	Non-pharmaceutication Non-	Both	Undetermined		
	Fentanyl	14%	86%	0%	0%		
NS	Fentanyl analogues	0%	100%	0%	0%		
	Non-fentanyl opioids	94%	2%	4%	0%		
	Fentanyl	n/a	n/a	n/a	n/a		
PE	Fentanyl analogues	Fentanyl 14% 86% Fentanyl analogues 0% 100% Non-fentanyl opioids 94% 2% Fentanyl analogues n/a n/a Non-fentanyl opioids n/a n/a Fentanyl analogues n/a n/a Fentanyl analogues n/a n/a Non-fentanyl opioids n/a n/a Fentanyl analogues n/a n/a Fentanyl analogues n/a n/a Fentanyl analogues n/a n/a Non-fentanyl opioids n/a n/a Fentanyl analogues n/a n/a Non-fentanyl opioids n/a n/a Fentanyl n/a n/a Fentanyl analogues n/a n/a Fentanyl analogues n/a n/a Fentanyl analogues n/a n/a Non-fentanyl opioids n/a n/a Fentanyl n/a n/a Fentanyl n/a n/a Fentanyl n/a n/a Fentanyl opioids n/a n/a Non-fentanyl opioids n/a n/a	n/a	n/a			
	Non-fentanyl opioids	n/a	n/a	n/a	n/a		
	Fentanyl	n/a	n/a	9% 0% 4% n/a n/a	n/a		
NL	Fentanyl analogues	n/a	n/a	n/a	n/a		
	Non-fentanyl opioids	n/a	n/a	n/a	n/a		
	Fentanyl	n/a	n/a	n/a n/a n/a n/a n/a n/a	n/a		
YT	Fentanyl analogues	n/a	n/a	n/a	n/a		
	Non-fentanyl opioids	n/a	n/a	n/a	n/a		
	Fentanyl	n/a	n/a	0% 0% 4% n/a	n/a		
NT	Fentanyl analogues	n/a	n/a	n/a	n/a		
	Non-fentanyl opioids	n/a	n/a	n/a	n/a		
	Fentanyl	n/a	n/a	n/a	n/a		
NU	Fentanyl analogues	n/a	n/a	n/a			
	Non-fentanyl opioids	n/a	n/a	n/a	n/a		
	Fentanyl	2%	98%	0%	0%		
Canada	Fentanyl analogues	0%	100%	0%	0%		
	Non-fentanyl opioids	67%	20%	5%	8%		

	Type of opioids		Origin				
Province or territory		Pharmaceutical only	Non-pharmaceutical only	Both	Undetermined		
	Fentanyl	0%	100%	0%	0%		
BC	Fentanyl analogues	0%	100%	0%	0%		
	Non-fentanyl opioids	0%	0%	0%	100%		
	Fentanyl	0%	100%	0%	0%		
AB	Fentanyl analogues	0%	100%	0%	0%		
	Non-fentanyl opioids	53%	Non-pharmaceutical only 100% 100% 0% 100%	2%	21%		
	Fentanyl	5%	95%	0%	0%		
SK	Fentanyl analogues	opioids Pharmaceutical only Non-pharmaceutical only anyl 0% 100% nalogues 0% 100% anyl 0% 100% anyl 0% 100% nalogues 0% 100% anyl 5% 95% nalogues 0% 100% anyl 3% 97% nalogues 0% 100% anyl 3% 97% nalogues 0% 10% anyl 3% 98% nalogues 0% 100% anyl 3% 16% anyl n/a n/a nalogues n/a n/a anyl 20% 80% nalogues n/a n/a anyl 20% 4% anyl 33% 67% nalogues 0% 100%	0%	0%			
	Non-fentanyl opioids	90%	4%	0%	6%		
	Fentanyl	3%	97%	0%	0%		
MB	Fentanyl analogues	0%	100%	0%	0%		
	Non-fentanyl opioids	76%	10%	3%	10%		
	Fentanyl	3%	98%	0%	0%		
ON	Fentanyl analogues	0%	100%	0%	0%		
	Non-fentanyl opioids	73%	16%	4%	6%		
	Fentanyl	n/a	n/a	n/a	n/a		
QC	Fentanyl analogues	n/a	n/a	n/a	n/a		
	Non-fentanyl opioids	n/a	n/a	n/a	n/a		
	Fentanyl	20%	80%	0%	0%		
NB	Fentanyl analogues	n/a	n/a	n/a	n/a		
	Non-fentanyl opioids	92%	4%	only Both 100% 0% 100% 0% 0% 0% 100% 0% 100% 0% 24% 2% 95% 0% 100% 0% 4% 0% 97% 0% 100% 0% 100% 0% 16% 4% n/a n/a n/a n/a n/a n/a n/a n/a 4% 0% 67% 0% 100% 0%	4%		
	Fentanyl	33%	67%	0%	0%		
NS	Fentanyl analogues	0%	100%	0%	0%		
	Non-fentanyl opioids	100%	0%	0%	0%		

D		Origin			
territory	Type of opioids	Pharmaceutical only	Non-pharmaceutical only	Both	Undetermined
	Fentanyl	n/a	n/a	n/a	n/a
PE	Fentanyl analogues	n/a	n/a	n/a	n/a
	Fentanyl n/a Fentanyl analogues n/a Non-fentanyl opioids n/a Fentanyl analogues n/a Fentanyl analogues n/a Non-fentanyl opioids n/a Fentanyl n/a Fentanyl n/a Fentanyl n/a Fentanyl opioids n/a Non-fentanyl opioids n/a Fentanyl n/a Fentanyl n/a Fentanyl n/a Fentanyl n/a Fentanyl analogues n/a Non-fentanyl opioids n/a Fentanyl analogues n/a Non-fentanyl opioids n/a Fentanyl n/a Fentanyl n/a Fentanyl n/a Fentanyl n/a Fentanyl opioids n/a	n/a	n/a	n/a	
	Fentanyl	n/a	n/a	n/a	n/a
NL	Fentanyl analogues	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a
	Fentanyl	n/a	n/a	n/a	n/a
YT	Fentanyl analogues	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a
	Fentanyl	n/a	n/a	n/a	n/a
NT	Fentanyl analogues	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a
	Fentanyl	n/a	n/a	n/a	n/a
NU	Fentanyl analogues	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a
	Fentanyl	2%	98%	0%	0%
Canada	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	72%	15%	3%	9%

			Origin		
Province or territory	Type of opioids	Pharmaceutical only	Non-pharmaceutical only	Both	Undetermined
	Fentanyl	0%	100%	0%	0%
ВС	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	0%	0%	Both 6 0% 6 0% 6 0% 6 0% 6 0% 6 0% 6 0% 6 0% 6 0% 6 0% 6 0% 6 0% 7 0% 8 0% 8 0% 9 0% 1 0%	100%
	Fentanyl	0%	100%	0%	0%
AB	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	48%	17%	4%	31%
	Fentanyl	1%	99%	0%	0%
SK	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	80%	5%	2%	13%
	Fentanyl	1%	59%	0%	39%
MB	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	17%	27%	1%	55%
	Fentanyl	1%	99%	0% 0% 0% 0% 0% 0% 4% 0% 0% 2% 0% 0% 1% 0% 4% 0% 0% 1% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%	0%
ON	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	78%	12%	4%	6%
	Fentanyl	n/a	n/a	n/a	n/a
QC	Fentanyl analogues	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a
	Fentanyl	0%	100%	0%	0%
NB	Fentanyl analogues	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	91%	0%	0% 0% 0% 0% 0% 0% 0% 4% 0% 0% 2% 0% 0% 1% 0% 4% 0% 1% 0% 0% 0% 4% n/a n/a n/a 0% 0% 0%	9%
NB	Fentanyl	20%	80%	0%	0%
NS	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	100%	0%	0%	0%

B			Origin				
Province or territory	Type of opioids	Pharmaceutical only	Non-pharmaceutical only	Both	Undetermined		
	Fentanyl	n/a	n/a	n/a	n/a		
PE	Fentanyl analogues	n/a	n/a	n/a	n/a		
	Non-fentanyl opioids	n/a	n/a	n/a	n/a		
	Fentanyl	Suppr.	Suppr.	0%	0%		
NL	Fentanyl analogues	Pharmaceutical only n/a n/a n/a n/a n/a n/a n/a n/	0%	Suppr.			
	Non-fentanyl opioids	100%	0%	0%	0%		
	Fentanyl	n/a	Non-pharmaceutical only B n/a r n/a r n/a r suppr. 0 suppr. 0 n/a r n/a r	n/a	n/a		
YT	Fentanyl analogues	n/a	n/a	n/a	n/a		
	Non-fentanyl opioids	n/a	n/a	n/a	n/a		
	Fentanyl	n/a	n/a	n/a n/a n/a n/a 0% 0% 0% n/a n/a	n/a		
NT	Fentanyl analogues	n/a	n/a	n/a	n/a		
	Non-fentanyl opioids	n/a	n/a	n/a	n/a		
	Fentanyl	n/a	n/a	n/a	n/a		
NU	Fentanyl analogues	Fentanyl n/a	n/a	n/a			
	Non-fentanyl opioids	n/a	n/a	n/a	n/a		
NU	Fentanyl	1%	97%	0%	2%		
Canada	Fentanyl analogues	0%	100%	0%	0%		
	Non-fentanyl opioids	67%	13%	3%	17%		

			Origin				
Province or territory	Type of opioids	Pharmaceutical only	Non-pharmaceutical only	Both	Undetermined		
	Fentanyl	0%	100%	0%	0%		
ВС	Fentanyl analogues	0%	100%	0%	0%		
	Non-fentanyl opioids	0%	0%	0%	100%		
	Fentanyl	0%	100%	0%	0%		
AB	Fentanyl analogues	0%	100%	0%	0%		
	Non-fentanyl opioids	32%	19%	3%	46%		
	Fentanyl	0%	100%	0%	0%		
SK	Fentanyl analogues	0%	charmaceutical only Non-pharmaceutical only 0% 100% 0% 100% 0% 0% 0% 100% 0% 100% 32% 19% 0% 100%	0%	0%		
	Non-fentanyl opioids	87%	3%	0%	9%		
	Fentanyl	1%	94%	0%	5%		
MB	Fentanyl analogues	0%	100%	0%	0%		
	Non-fentanyl opioids	0%	68%	0%	32%		
	Fentanyl	0%	100%	0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%	0%		
ON	Fentanyl analogues	0%	100%	0%	0%		
	Non-fentanyl opioids	78%	10%	4%	8%		
	Fentanyl	n/a	n/a	n/a	n/a		
QC	Fentanyl analogues	n/a	n/a	n/a	n/a		
	Non-fentanyl opioids	n/a	n/a	n/a	n/a		
	Fentanyl	0%	100%	0%	0%		
NB	Non-fentanyl opioids Fentanyl O% Fentanyl analogues O% Non-fentanyl opioids Fentanyl I% Fentanyl analogues O% Non-fentanyl opioids O% Fentanyl opioids O% Fentanyl O% Fentanyl opioids Fentanyl opioids Fentanyl opioids Fentanyl opioids Fentanyl opioids Fentanyl Non-fentanyl opioids Fentanyl Non-fentanyl opioids Fentanyl Non-fentanyl opioids Fentanyl O% Fentanyl opioids Fentanyl O% Fentanyl opioids Fentanyl O% Fentanyl opioids O% Non-fentanyl opioids Fentanyl O% Fentanyl opioids	0%	100%	0%	0%		
	Non-fentanyl opioids	94%	0%	0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0	6%		
	Fentanyl	0%	100%	0%	0%		
NS	Fentanyl analogues	0%	100%	0%	0%		
	Non-fentanyl opioids	100%	0%	0%	0%		

Province or			Origin				
territory	Type of opioids	Pharmaceutical only	Non-pharmaceutical only	Both	Undetermined		
	Fentanyl	0%	0%	0%	0%		
PE	Fentanyl analogues	0%	0%	0%	0%		
	Non-fentanyl opioids	58%	0%	0%	42%		
	Fentanyl	Suppr.	Suppr.	0%	83%		
NL	Fentanyl analogues	Pharmaceutical only 0% 0% 0% 0% 58% 0%	0%	0%			
	Non-fentanyl opioids	Suppr.	0%	Suppr.	88%		
	Fentanyl	S 0% 0% 0% Suppr. Suppr. Suppr. Suppr. Suppr. Suppr. O% 0% 18 Suppr. 0% 1/4 n/4 100% 100% 100% 100% 100% 100% 100% 100	n/a	n/a			
YT	Fentanyl analogues	n/a	n/a	n/a	n/a		
	Non-fentanyl opioids	n/a	n/a	n/a	n/a		
	Fentanyl	0%	100%	atical Both 0% 0% 0% 0% 0% 0% Suppr. n/a	0%		
NT	Fentanyl analogues	0%	0%	0%	0%		
	Non-fentanyl opioids	67%	33%	0%	0%		
	Fentanyl	n/a	n/a	n/a	n/a		
NU	Fentanyl analogues	Non-pharmaceutical only 0 0 0 0 0 0 0 0 0	n/a	n/a			
-	Non-fentanyl opioids	n/a	n/a	n/a	n/a		
NU	Fentanyl	0%	99%	0%	0%		
Canada	Fentanyl analogues	0%	100%	0%	0%		
	Non-fentanyl opioids	60%	17%	3%	20%		

			Origin		
Province or territory	Type of opioids	Pharmaceutical only	Non-pharmaceutical only	Both	Undetermined
	Fentanyl	0%	100%	0%	0%
BC	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	0%	0%	Both	100%
	Fentanyl	0%	100%	0%	0%
AB	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	37%	9%	1%	52%
	Fentanyl	1%	99%	0%	0%
SK	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	93%	1%	3%	3%
	Fentanyl	0%	96%	0%	4%
MB	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	0%	44%	0%	56%
	Fentanyl	0%	100%	only soft o% o% o% o%	0%
ON	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	77%	8%	3%	11%
	Fentanyl	n/a	n/a	n/a	n/a
QC	Fentanyl analogues	n/a	n/a	n/a	n/a
	Non-fentanyl opioids	n/a	n/a	n/a	n/a
	Fentanyl	0%	100%	0%	0%
NB	Fentanyl analogues	Pharmaceutical only Non-pharmace only 0% 100% 100% 100% pioids 0% 100% pioids 0% 100% pioids 37% 9% pioids 93% 1% pioids 93% 1% pioids 0% 96% pioids 0% 100% pioids 0% 100% pioids 77% 8% n/a n/a n/a pioids n/a n/a pioids n/a n/a pioids 90% 100% pioids 90% 100%	100%	0%	0%
	Non-fentanyl opioids	90%	10%	Secutical Soth	0%
	Fentanyl	0%	100%	0%	0%
NS	Fentanyl analogues	0%	100%	0%	0%
	Non-fentanyl opioids	92%	8%	0%	0%

Province or		Origin				
territory	Type of opioids	Pharmaceutical only Fentanyl O% O% O% O% O% Intanyl opioids Fentanyl O% O% O% O% O% O% O% O% O% O	Both	Undetermined		
	Fentanyl	0%	0%	0%	0%	
PE	Fentanyl analogues	0%	0%	0%	0%	
	Fentanyl 0% 0% Fentanyl opioids 0% 0% Fentanyl opioids 0% 0% Non-fentanyl opioids 0% 0% Fentanyl analogues 0% 0% Fentanyl analogues 0% 0% Fentanyl analogues 0% 0% Non-fentanyl opioids Suppr. 0% Fentanyl n/a n/a Fentanyl analogues n/a n/a Non-fentanyl opioids n/a n/a Fentanyl analogues 0% 0% Fentanyl n/a n/a Fentanyl opioids n/a n/a Fentanyl analogues 0% 0% Fentanyl analogues 0% 0% Fentanyl analogues 0% 0% Non-fentanyl opioids 0% 0% Fentanyl n/a n/a Fentanyl n/a n/a Fentanyl n/a n/a Fentanyl opioids n/a n/a	0%	100%			
	Fentanyl	0%	0%	Suppr.	Suppr.	
NL	Fentanyl analogues	Pharmaceutical only Non-pharmaceutical only byl 0% 0% alogues 0% 0% opioids 0% 0% opioids 0% 0% alogues 0% 0% opioids Suppr. 0% opioids n/a n/a opioids n/a n/a opioids 0% 0% opioids 0% 0% opioids 0% 0% opioids n/a n/a opioids n/a n/a <td>0%</td> <td>0%</td>	0%	0%		
	Non-fentanyl opioids	Suppr.	0%	Suppr.	94%	
	Fentanyl	n/a	Non-pharmaceutical only 0% 0% 0% 0% 0% 0% 0% 0% 0% 0	n/a	n/a	
YT	Fentanyl analogues	n/a	n/a	n/a	n/a	
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	
	Fentanyl	0%	0%	0%	0%	
NT	Fentanyl analogues	0%	0%	0%	0%	
	Non-fentanyl opioids	0%	0%	0%	0%	
	Fentanyl	n/a	n/a	n/a	n/a	
NU	Fentanyl analogues	n/a	n/a	n/a	n/a	
	Non-fentanyl opioids	n/a	n/a	n/a	n/a	
	Fentanyl	0%	100%	0%	0%	
Canada	Fentanyl analogues	0%	100%	0%	0%	
	Non-fentanyl opioids	64%	9%	2%	24%	

Only applies to deaths with completed investigations.

Suppressed (Suppr.) Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules.

Not available (n/a) Data were not available at the time of this publication.

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants. 2022 data from Manitoba are based on January to March.

Table 18. Percentage of accidental apparent opioid toxicity deaths by sex and origin of opioid(s), by province or territory, 2018 to 2022

Province or territory	Origin						
	Sex	Pharmaceutical only	Non-pharmaceutical only	Both	Undetermined		
DO	Female	0%	55%	0%	45%		
BC	Male	0%	63%	0%	37%		
AB	Female	28%	65%	1%	7%		
AB	Male	11%	83%	1%	4%		
SK	Female	77%	17%	4%	2%		
SK	Male	45%	48%	4%	3%		
MB	Female	n/a	n/a	n/a	n/a		
MB	Male	n/a	n/a	n/a	n/a		
	Female	31%	59%	7%	4%		
ON	Male	20%	67%	11%	3%		
	Female	n/a	n/a	n/a	n/a		
QC	Male	n/a	n/a	n/a	n/a		
	Female	100%	0%	0%	0%		
NB	Male	90%	0%	10%	0%		
	Female	81%	6%	13%	0%		
NS	Male	88%	6%	6%	0%		
	Female	n/a	n/a	n/a	n/a		
PE -	Male	n/a	n/a	n/a	n/a		
	Female	n/a	n/a	n/a	n/a		
NL	Male	n/a	n/a	n/a	n/a		
	Female	n/a	n/a	n/a	n/a		
YT	Male	n/a	n/a	n/a	n/a		
NIT	Female	n/a	n/a	n/a	n/a		
NT	Male	n/a	n/a	n/a	n/a		
	Female	n/a	n/a	n/a	n/a		
NU	Male	n/a	n/a	n/a	n/a		
	Female	36%	55%	5%	4%		
Canada	Male	20%	70%	7%	3%		

Province or			Origin		
territory	Sex	Pharmaceutical only	Non-pharmaceutical only	Both	Undetermined
DO.	Female	1%	56%	0%	43%
BC	Male	0%	70%	0%	30%
AB	Female	24%	66%	0%	10%
AB	Male	13%	81%	1%	5%
01/	Female	69%	26%	3%	3%
SK	Male	54%	34%	6%	6%
MAD	Female	71%	24%	0%	6%
MB	Male	24%	65%	5%	5%
0.11	Female	29%	57%	10%	4%
ON	Male	14%	72%	12%	2%
00	Female	n/a	n/a	n/a	n/a
QC	Male	n/a	n/a	n/a	n/a
ND	Female	100%	0%	0%	0%
NB	Male	62%	23%	8%	8%
NO	Female	100%	0%	0%	0%
NS	Male	90%	6%	3%	0%
D.E.	Female	n/a	n/a	n/a	n/a
PE	Male	n/a	n/a	n/a	n/a
	Female	n/a	n/a	n/a	n/a
NL	Male	n/a	n/a	n/a	n/a
\ (T	Female	n/a	n/a	n/a	n/a
YT	Male	n/a	n/a	n/a	n/a
NIT	Female	n/a	n/a	n/a	n/a
NT	Male	n/a	n/a	n/a	n/a
NILL	Female	n/a	n/a	n/a	n/a
NU	Male	n/a	n/a	n/a	n/a
Canada	Female	34%	54%	6%	5%
Canada	Male	18%	71%	8%	3%

Province or territory	Sex	Origin				
		Pharmaceutical only	Non-pharmaceutical only	Both	Undetermined	
ВС	Female	0%	70%	0%	30%	
	Male	0%	80%	0%	20%	
AB	Female	16%	75%	1%	8%	
	Male	7%	86%	1%	6%	
SK	Female	43%	40%	9%	8%	
	Male	26%	60%	8%	6%	
MB	Female	5%	42%	3%	49%	
	Male	8%	44%	1%	47%	
ON -	Female	18%	68%	13%	2%	
	Male	8%	81%	9%	1%	
QC -	Female	n/a	n/a	n/a	n/a	
	Male	n/a	n/a	n/a	n/a	
NB -	Female	76%	6%	0%	18%	
	Male	85%	15%	0%	0%	
NS -	Female	100%	0%	0%	0%	
	Male	70%	19%	11%	0%	
DE	Female	n/a	n/a	n/a	n/a	
PE	Male	n/a	n/a	n/a	n/a	
NL -	Female	Suppr.	Suppr.	0%	0%	
	Male	Suppr.	Suppr.	0%	0%	
YT	Female	n/a	n/a	n/a	n/a	
	Male	n/a	n/a	n/a	n/a	
NT	Female	n/a	n/a	n/a	n/a	
	Male	n/a	n/a	n/a	n/a	
NU -	Female	n/a	n/a	n/a	n/a	
	Male	n/a	n/a	n/a	n/a	
Canada -	Female	20%	63%	8%	8%	
	Male	10%	78%	6%	5%	

Province or territory	Sex	Origin				
		Pharmaceutical only	Non-pharmaceutical only	Both	Undetermined	
ВС	Female	0%	71%	0%	29%	
	Male	0%	81%	0%	19%	
AB	Female	9%	85%	1%	6%	
	Male	4%	89%	0%	7%	
SK	Female	23%	66%	11%	1%	
	Male	9%	74%	14%	4%	
MB	Female	0%	84%	0%	16%	
	Male	1%	81%	1%	18%	
ON	Female	8%	77%	12%	3%	
	Male	6%	83%	10%	1%	
	Female	n/a	n/a	n/a	n/a	
QC	Male	n/a	n/a	n/a	n/a	
NB	Female	75%	6%	6%	13%	
	Male	86%	10%	5%	0%	
NO.	Female	100%	0%	0%	0%	
NS	Male	67%	33%	0%	0%	
DE.	Female	75%	0%	0%	25%	
PE -	Male	50%	0%	0%	50%	
A.I.	Female	Suppr.	Suppr.	0%	86%	
NL	Male	Suppr.	Suppr.	0%	86%	
YT	Female	n/a	n/a	n/a	n/a	
	Male	n/a	n/a	n/a	n/a	
NT	Female	100%	0%	0%	0%	
	Male	33%	67%	0%	0%	
NU -	Female	n/a	n/a	n/a	n/a	
	Male	n/a	n/a	n/a	n/a	
Canada	Female	10%	77%	7%	5%	
	Male	6%	83%	7%	5%	

Province or territory	Sex	Origin				
		Pharmaceutical only	Non-pharmaceutical only	Both	Undetermined	
ВС	Female	0%	68%	0%	33%	
	Male	1%	81%	0%	18%	
АВ	Female	8%	82%	0%	10%	
	Male	5%	87%	0%	8%	
SK	Female	25%	63%	11%	1%	
	Male	16%	74%	9%	1%	
MB	Female	0%	59%	0%	41%	
	Male	0%	65%	0%	35%	
ON	Female	15%	73%	8%	4%	
	Male	8%	82%	8%	2%	
00	Female	n/a	n/a	n/a	n/a	
QC	Male	n/a	n/a	n/a	n/a	
ND	Female	69%	31%	0%	0%	
NB	Male	43%	57%	0%	0%	
NC	Female	75%	13%	13%	0%	
NS -	Male	74%	21%	5%	0%	
DE	Female	0%	0%	0%	100%	
PE -	Male	0%	0%	0%	100%	
N.I.	Female	Suppr.	Suppr.	0%	86%	
NL	Male	Suppr.	Suppr.	0%	100%	
	Female	n/a	n/a	n/a	n/a	
YT	Male	n/a	n/a	n/a	n/a	
NT	Female	0%	0%	0%	0%	
	Male	0%	0%	0%	0%	
NU -	Female	n/a	n/a	n/a	n/a	
	Male	n/a	n/a	n/a	n/a	
Canada	Female	15%	72%	5%	8%	
	Male	8%	81%	5%	5%	

Only applies to deaths with completed investigations.

Suppressed (Suppr.) Data may be suppressed in provinces or territories with low numbers of cases in order to comply with confidentiality rules.

Not available (n/a) Data were not available at the time of this publication.

Note(s):

Apparent opioid toxicity death (AOTD): A death caused by intoxication/toxicity (poisoning) resulting from substance use, where one or more of the substances is an opioid, regardless of how it was obtained (e.g., illegally or through personal prescription). Other substances may also be involved.

Data on apparent opioid toxicity deaths and stimulant toxicity deaths are not mutually exclusive. A high proportion of deaths involving a stimulant also involved an opioid. Adding up those numbers would result in an overestimation of the burden of opioids and stimulants. 2022 data from Manitoba are based on January to March.